Document:

EX-10.4 SIXTH AMENDMENT/CREDIT AGREEMENT & CONSENT

 

Exhibit
10.4

SIXTH AMENDMENT TO CREDIT AGREEMENT AND CONSENT

     This SIXTH AMENDMENT TO CREDIT AGREEMENT AND CONSENT (this “Amendment”) dated as of
October 13, 2006, by and among AGCO CORPORATION, a Delaware corporation (“AGCO”), AGCO
CANADA, LTD., a Saskatchewan corporation (“Canadian Subsidiary”), AGCO LIMITED, an English
corporation (“English Subsidiary One”), AGCO INTERNATIONAL LIMITED, an English corporation
(“English Subsidiary Two”), AGCO HOLDING B.V., a Netherlands corporation (“Netherlands
Subsidiary”), AGCO DEUTSCHLAND HOLDING LIMITED & CO. KG, a German limited partnership
(“German Subsidiary”), and VALTRA HOLDING OY, a Finnish limited liability company
(“Finnish Subsidiary”; AGCO, Canadian Subsidiary, English Subsidiary One, English
Subsidiary Two, Netherlands Subsidiary, German Subsidiary and Finnish Subsidiary are referred to
herein collectively as the “Borrowers” and individually as a “Borrower”); the
lenders (the “Lenders”) signatory hereto; COÖPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK
B.A., “RABOBANK NEDERLAND”, CANADIAN BRANCH, as Canadian administrative agent for the Canadian
Lenders (together with any successor, in such capacity, the “Canadian Administrative
Agent”); and COÖPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A., “RABOBANK NEDERLAND”, NEW
YORK BRANCH, as administrative agent for the Lenders (together with any successor, in such
capacity, the “Administrative Agent”).

W I T N E S S E T H:

     WHEREAS, the Borrowers, the Administrative Agent, the Canadian Administrative Agent, the
Lenders, the Issuing Banks (as defined in the Credit Agreement), SunTrust Bank and Morgan Stanley
Senior Funding, Inc., as Co-Syndication Agents, and CoBank, ACB and The Bank of Tokyo-Mitsubishi,
Ltd., NY Branch, as Co-Documentation Agents, are parties to that certain Credit Agreement dated as
of December 22, 2003 (as amended by that certain First Amendment to Credit Agreement and Consent
dated as of April 12, 2004, as further amended by that certain Second Amendment to Credit Agreement
dated as of August 17, 2004, as further amended by that certain Third Amendment to Credit Agreement
dated as of March 21, 2005, as further amended by that certain Fourth Amendment to Credit Agreement
and Consent dated as of June 2, 2005, as further amended by that certain Fifth Amendment to Credit
Agreement dated as of March 22, 2006 and as further amended, restated, supplemented or modified
from time to time, the “Credit Agreement”); and

     WHEREAS, the Borrowers have requested that certain terms and conditions of the Credit
Agreement be amended, and the Lenders signatory hereto, the Canadian Administrative Agent and the
Administrative Agent have agreed to the requested amendments on the terms and conditions set forth
herein; and

 

 

     WHEREAS, the Borrowers intend to refinance the outstanding obligations under the European
Securitization with the proceeds of a new securitization facility (the “New European
Securitization Facility”) consummated pursuant to the term and conditions hereof; and

     WHEREAS, in connection with such refinancing, the receivables subject to the new
securitization facility will be transferred to AGCO Receivables Limited, a qualifying special
purpose entity, which will be a wholly-owned indirect Subsidiary of AGCO but which will not be a
Restricted Subsidiary under the Credit Agreement as its accounts will not be, under GAAP,
Consolidated with the accounts of AGCO; and

     WHEREAS, to the extent required under the Credit Agreement, the Borrowers have requested that
the Agents and the Lenders consent to the consummation of the transactions contemplated in the New
Securitization Facility, and the Lenders signatory hereto and the Agents have consented to the
transactions contemplated in the New Securitization Facility on the terms and conditions set forth
herein;

     NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements
contained herein, the parties hereto hereby agree that all capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Credit Agreement, and further agree as
follows:

     Section 1. Amendments to Section 1.1. Section 1.1 of the Credit Agreement, Certain
Defined Terms, is hereby amended and modified by deleting the definitions of European
Securitization and European Securitization Documents in their entirety and by substituting the
following in lieu thereof:

““European Securitization” means funding in connection with sales by certain
Foreign Subsidiaries of AGCO of wholesale Receivables invoiced to third parties at
addresses located in Europe to special purpose entity, as more fully set forth in the
European Securitization Documents.”

““European Securitization Documents” means (a) that certain Receivables Transfer
Agreement among AGCO Receivables Limited, French Subsidiary, English Subsidiary One and
Rabobank London dated October 13, 2006, (b) that certain Receivables Transfer Agreement
among AGCO Receivables Limited, AGCO Iberia S.A., English Subsidiary One and Rabobank
London dated October 13, 2006, (c) that certain Receivables Transfer Agreement among AGCO
Receivables Limited, AGCO GMBH, English Subsidiary One and Rabobank London dated October
13, 2006, (d) that certain Receivables Funding Agreement among AGCO Receivables Limited,
Erasmus Capital Corporation and Rabobank London dated October 13, 2006, (e) that certain
Subordinated Loan Agreement among AGCO Receivables Limited, AGCO Services Limited, English
Subsidiary One and Rabobank London dated October 13, 2006, (f) that certain Parent
Undertaking Agreement among AGCO Receivables Limited, AGCO and

-2-

 

Rabobank London dated October 13, 2006, (g) the Repurchase and Termination Agreement among
Erasmus Capital Corporation, Rabobank London, AGCO, AGCO Services Limited, English
Subsidiary One, AGCO Vertriebs GmbH, AGCO GmbH, AGCO S.A. and AGCO Iberia SA dated October
13, 2006 and (h) all other agreements executed in connection with the foregoing, as the
same may be amended, supplemented, modified or replaced from time to time with the consent
of the Administrative Agent.”

     Section 2. Consent to New European Securitization Facility. Notwithstanding the
limitations set forth in Sections 7.2 (Limitations on Guaranties), 7.8 (Investments) and 7.11
(Affiliate Transactions) of the Credit Agreement, the Agents and the Lenders hereby consent to (i)
the Investments made or to be made pursuant to (A) that certain Subordinated Loan Agreement, dated
October 13, 2006, among AGCO Receivables Limited, AGCO Services Limited, English Subsidiary One and
Rabobank London, and (B) the other European Securitization Documents (as such term has been amended
herein); (ii) the guaranties by AGCO of payment of fees, indemnification obligations and
performance obligations of AGCO Receivables Limited pursuant to (A) that certain Parent Undertaking
Agreement, dated October 13, 2006, among AGCO Receivables Limited, AGCO and Rabobank London, and
(B) the other European Securitization Documents (as such term has been amended herein), and (iii)
the transactions among AGCO Receivables Limited, on the one hand, and the Borrowers and their
Restricted Subsidiaries, on the other hand, contemplated by the European Securitization Documents,
provided that (i) giving effect to this Amendment, no Default or Event of Default shall
have occurred and be continuing at the time European Securitization Documents (as such term has
been amended herein) become effective and (ii) the European Securitization Documents (as such term
has been amended herein) shall be delivered to the Administrative Agent promptly after the closing
thereof. Additionally, the Agents and Lenders agree that in connection with any other Investment
during this fiscal year or otherwise, the Investments made pursuant to European Securitization
Documents (as such term has been amended herein) shall not be included in calculating the U.S.
$15,000,000 per fiscal year limit and U.S. $30,000,000 aggregate limit set forth in Section
7.8(e)(ii) of the Credit Agreement.

     Section 3. Representations and Warranties. Each of AGCO and the other Borrowers
represents and warrants as follows:

               (a) The execution, delivery and performance by each Borrower of this Amendment and the other
transactions contemplated hereby, are within such Borrower’s corporate powers, have been duly
authorized by all necessary corporate action, and do not (i) contravene such Borrower’s charter or
bylaws; (ii) violate any Applicable Law (including, without limitation, to the extent applicable,
the Securities Exchange Act of 1934, the Racketeer Influenced and Corrupt Organizations Chapter of
the Organized Crime Control Act of 1970 and any similar statute); (iii) conflict with or result in
the breach of, or constitute a default under, any contract, loan agreement,

-3-

 

indenture, mortgage, deed of trust, lease or other instrument binding on or affecting any
Borrower, any of its Subsidiaries or any of their properties (including any of the Applicable
Capital Market Transaction Documents); or (iv) except for Permitted Liens, result in or require the
creation or imposition of any Lien upon or with respect to any of the properties of any Borrower or
any of its Restricted Subsidiaries;

               (b) No authorization or approval or other action by, and no notice to or filing with, any
Governmental Authority or regulatory body or any other third party is required for the due
execution, delivery or performance by any Borrower of this Amendment and each other Loan Document
contemplated hereby to which it is or is to be a party;

               (c) This Amendment and each other document required to be delivered by a Borrower hereunder
has been duly executed and delivered by each Borrower thereto, and constitutes the legal, valid and
binding obligation of each Borrower thereto, enforceable against such Borrower in accordance with
its terms;

               (d) The representations and warranties contained in Article 4 of the Credit Agreement, and in
each of the other Loan Documents, are true and correct on and as of the date hereof as though made
on and as of such date, other than (i) any such representations and warranties that, by their
terms, expressly refer to an earlier date, and (ii) as a result of changes permitted by the terms
of the Credit Agreement; and

               (e) After giving effect hereto, no event has occurred and is continuing which constitutes an
Event of Default or would constitute an Event of Default but for the requirement that notice be
given or time elapse or both.

     Section 4. Conditions Precedent to Effectiveness of this Amendment. This Amendment
shall be effective as of the date first set forth above when the Administrative Agent shall have
received, in form and substance satisfactory to it, each of the following:

               (a) this Amendment, duly executed by the Borrowers, the Canadian Administrative Agent and the
Administrative Agent, and Lender Addenda, in the form attached hereto, duly executed by the
Required Lenders; and

               (b) the delivery of such other documents, instruments and information, as the Administrative
Agent may reasonably request.

-4-

 

     Section 5. Reference to and Effect on the Credit Agreement. Upon the effectiveness of
this Amendment as set forth in Section 4 hereof, on and after the date hereof, each reference in
the Credit Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of like import
shall mean and be a reference to the Credit Agreement as amended hereby, and each reference in the
Notes and the other Loan Documents to the Credit Agreement shall mean and be a reference to the
Credit Agreement as amended hereby.

     Section 6. Reaffirmation of Guaranty. By executing this Amendment, each Guarantor
hereby acknowledges, consents and agrees that all of its obligations and liability under the
Guaranty Agreements to which it is a party remain in full force and effect, and that the execution
and delivery of this Amendment and any and all documents executed in connection therewith shall not
alter, amend, reduce or modify its obligations and liability under such Guaranty Agreements or any
of the other Loan Documents to which it is a party.

     Section 7. Costs, Expenses and Taxes. The Borrowers agree, jointly and severally, to
pay on demand all costs and expenses of the Administrative Agent in connection with the
preparation, execution and delivery of this Amendment and the other instruments and documents to be
delivered hereunder (including, without limitation, the fees and expenses of counsel for the
Administrative Agent with respect thereto).

     Section 8. No Other Amendments. Except as otherwise expressed herein, the execution,
delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or
remedy of the Agents or the Lenders under the Credit Agreement, or any of the other Loan Documents,
nor constitute a waiver of any provision of the Credit Agreement or any of the other Loan
Documents. Except for the amendments set forth above, the text of the Credit Agreement and all
other Loan Documents shall remain unchanged and in full force and effect and the Borrowers hereby
ratify and confirm their respective obligations thereunder. This Amendment shall not constitute a
modification of the Credit Agreement or a course of dealing with the Administrative Agent at
variance with the Credit Agreement such as to require further notice by the Administrative Agent to
require strict compliance with the terms of the Credit Agreement and the other Loan Documents in
the future, except as expressly set forth herein. The Borrowers acknowledge and expressly agree
that the Agents and the Lenders reserve the right to, and do in fact, require strict compliance
with all terms and provisions of the Credit Agreement and the other Loan Documents (in each case as
amended hereby).

     Section 9. Execution in Counterparts. This Amendment may be executed in any number of
counterparts, each of which when so executed and delivered shall be deemed to be an original and
all of which taken together shall constitute but one and the same instrument. Delivery of a
signature page hereto by facsimile transmission or via email transmission of an Adobe portable
document format file (also known as a “PDF File”) shall be as effective as delivery of a manually
executed counterpart hereof.

-5-

 

     Section 10. Delivery of Lender Addenda. Each Lender executing this Amendment shall do
so by delivering to the Administrative Agent a Lender Addendum, substantially in the form of Annex
I attached hereto, duly executed by such Lender.

     Section 11. Governing Law. This Amendment shall be governed by, and construed in
accordance with, the laws (without giving effect to the conflicts of laws principles thereof) of
the State of New York.

     Section 12. Final Agreement. This Amendment represents the final agreement between
the Borrowers, the Administrative Agent, the Canadian Administrative Agent and the Lenders as to
the subject matter hereof and may not be contradicted by evidence of prior, contemporaneous or
subsequent oral agreements of the parties. There are no unwritten oral agreements between the
parties. The Amendment shall constitute a Loan Document for all purposes.

[the remainder of the page is intentionally blank]

-6-

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their
respective officers thereunto duly authorized, as of the date first above written.

BORROWERS:

	 	 	 	 	 	 	 	 	 
	 	 	AGCO CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO CANADA, LTD.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO LIMITED	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO INTERNATIONAL LIMITED	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO HOLDING B.V.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 

[SIGNATURES CONTINUED ON FOLLOWING PAGE]

Sixth Amendment to Credit Agreement and Consent

Signature Page 1

 

 

	 	 	 	 	 	 	 	 	 
	 	 	AGCO DEUTSCHLAND HOLDING LIMITED & CO. KG	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	VALTRA HOLDING OY	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	GUARANTORS:	 	VALTRA DEUTSCHLAND GMBH	 	 
	 	 	(formerly known as RM 2379	 	 
	 	 	VERMÖGENSVERWALTUNGS GMBH)	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO VERTRIEBS GMBH	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 

Sixth Amendment to Credit Agreement and Consent

Signature Page 2

 

 

	 	 	 	 	 	 	 	 	 
	 	 	AGCO GMBH	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO FRANCE S.A.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO S.A.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	VALTRA TRACTEURS FRANCE S.A.S.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	VALTRA INTERNATIONAL B.V.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 

Sixth Amendment to Credit Agreement and Consent

Signature Page 3

 

 

	 	 	 	 	 	 	 	 	 
	 	 	MASSEY FERGUSON CORP.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO EQUIPMENT COMPANY	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	SUNFLOWER MANUFACTURING COMPANY, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO MANUFACTURING LTD.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO SERVICES LTD.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 

Sixth Amendment to Credit Agreement and Consent

Signature Page 4

 

 

	 	 	 	 	 	 	 	 	 
	 	 	VALTRA VUOKRAUS OY	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGCO DO BRASIL COMERCIA E INDUSTRIA LTDA.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	VALTRA DO BRASIL LTDA.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	EXPORT MARKET SERVICES LLC	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 

[SIGNATURES CONTINUED ON FOLLOWING PAGE]

Sixth Amendment to Credit Agreement and Consent

Signature Page 5

 

 

	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	AGENTS, ISSUING BANKS 

AND SWING LINE BANK:	 	COÖPERATIEVE CENTRALE RAIFFEISEN-
BOERENLEENBANK B.A., “RABOBANK
NEDERLAND,” NEW YORK BRANCH, as
Administrative Agent and Multi-Currency Issuing Bank	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	COÖPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A.,
“RABOBANK NEDERLAND,” CANADIAN BRANCH, as Canadian
Administrative Agent and Canadian Issuing Bank	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	LENDERS:	 	See each Lender Addendum attached hereto	 	 

Sixth Amendment to Credit Agreement

Signature Page 7

 

 

LENDER ADDENDUM

          Reference is made to the Credit Agreement dated as of December 22, 2003 (as amended by that
certain First Amendment to Credit Agreement and Consent dated as of April 12, 2004, as further
amended by that certain Second Amendment to Credit Agreement dated as of August 17, 2004, as
further amended by that certain Third Amendment to Credit Agreement dated as of March 21, 2005 as
further amended by that certain Fourth Amendment to Credit Agreement and Consent dated as of June
2, 2005, as further amended by that certain Fifth Amendment to Credit Agreement dated as of March
22, 2006 and as further amended, restated, supplemented or modified from time to time, the
“Credit Agreement”) among AGCO Corporation, AGCO Canada Ltd., AGCO Limited, AGCO
International Limited, AGCO Holding B.V., AGCO Deutschland Holding Limited & Co. KG and Valtra
Holding Oy (collectively, the “Borrowers”), the lenders signatory thereto (together with
any other financial institution that subsequently becomes a Lender thereunder, the
“Lenders”), the Issuing Banks (as defined in the Credit Agreement), Coöperatieve Centrale
Raiffeisen-Boerenleenbank B.A., “Rabobank Nederland”, Canadian Branch, as Canadian Administrative
Agent, SunTrust Bank and Morgan Stanley Senior Funding, Inc., as Co-Syndication Agents, CoBank, ACB
and The Bank of Tokyo-Mitsubishi, Ltd., NY Branch, as Co-Documentation Agents, and Coöperatieve
Centrale Raiffeisen-Boerenleenbank B.A., “Rabobank Nederland”, New York Branch, as the
Administrative Agent (the “Administrative Agent”). Capitalized terms used herein without
definition shall have the respective meanings ascribed to those terms in the Credit Agreement.

          Upon execution and delivery of this Lender Addendum by the undersigned Lender, the undersigned
Lender hereby consents to and agrees with all of the terms and conditions contained in, and shall
become a party to, the Sixth Amendment to Credit Agreement and Consent dated as of October ___,
2006.

          THIS LENDER ADDENDUM SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH,
THE LAW OF THE STATE OF NEW YORK.

          This Lender Addendum may be executed by one or more of the parties hereto on any number of
separate counterparts, and all of said counterparts taken together shall be deemed to constitute
one and the same instrument. Delivery of an executed signature page hereof by facsimile
transmission or via email transmission of an Adobe portable document file (also known as a “PDF
File”) shall be effective as delivery of a manually executed counterpart hereof.

[The remainder of this page is intentionally left blank.]

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Lender Addendum to be duly executed
and delivered by their proper and duly authorized officers effective as of the date set forth
herein.

	 	 	 	 	 	 	 	 	 
	 	 	[NAME OF LENDER]	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	Name:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 	 	 

Lender Addendum

Signature PageEX-10.1 Nonqualified Deferred Compensation Plan

 

Exhibit 10.1

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

Effective January 1, 2006

As Amended and Restated September 15, 2006

 

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page	 
	ARTICLE 1   Definitions
	 	 	1	 
	 
	 	 	 	 
	ARTICLE 2 Selection, Enrollment, Eligibility
	 	 	7	 
	 
	 	 	 	 
	2.1 Selection by Committee
	 	 	7	 
	2.2 Enrollment and Eligibility Requirements; Commencement
of Participation
	 	 	7	 
	 
	 	 	 	 
	ARTICLE 3   Deferral Commitments/Company Contribution Amounts/Company
Restoration Matching Amounts/Restricted Stock Amounts
/Vesting/Crediting/Taxes
	 	 	8	 
	 
	 	 	 	 
	3.1 Minimum Deferrals
	 	 	8	 
	3.2 Maximum Deferral
	 	 	8	 
	3.3 Election to Defer; Effect of Election Form
	 	 	9	 
	3.4 Withholding and Crediting of Annual Deferral Amounts
	 	 	10	 
	3.5 Company Contribution Amount
	 	 	11	 
	3.6 Company Restoration Matching Amount
	 	 	11	 
	3.7 Restricted Stock Amount
	 	 	11	 
	3.7 Crediting of Amounts after Benefit Distribution
	 	 	11	 
	3.9 Vesting
	 	 	12	 
	3.10 Crediting/Debiting of Account Balances
	 	 	13	 
	3.11 FICA and Other Taxes
	 	 	15	 
	 
	 	 	 	 
	ARTICLE 4 Scheduled Distribution; Unforeseeable Emergencies
	 	 	16	 
	 
	 	 	 	 
	4.1 Scheduled Distribution
	 	 	16	 
	4.2 Postponing Scheduled Distributions
	 	 	16	 
	4.3 Other Benefits Take Precedence Over Scheduled Distributions
	 	 	16	 
	4.4 Unforeseeable Emergencies
	 	 	17	 
	 
	 	 	 	 
	ARTICLE 5 Change In Control Benefit
	 	 	18	 
	 
	 	 	 	 
	5.1 Change in Control Benefit
	 	 	18	 
	5.2 Payment of Change in Control Benefit
	 	 	18	 
	 
	 	 	 	 
	ARTICLE 6 Retirement Benefit
	 	 	18	 
	 
	 	 	 	 
	6.1 Retirement Benefit
	 	 	18	 
	6.2 Payment of Retirement Benefit
	 	 	18	 
	 
	 	 	 	 
	ARTICLE 7 Termination Benefit
	 	 	19	 
	 
	 	 	 	 
	7.1 Termination Benefit
	 	 	19	 
	7.2 Payment of Termination Benefit
	 	 	19	 

-i-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	 	 	 
	 	 	Page	 
	ARTICLE 8 Disability Benefit
	 	 	20	 
	 
	 	 	 	 
	8.1 Disability Benefit
	 	 	20	 
	8.2 Payment of Disability Benefit
	 	 	20	 
	 
	 	 	 	 
	ARTICLE 9 Death Benefit
	 	 	20	 
	 
	 	 	 	 
	9.1 Death Benefit
	 	 	20	 
	9.2 Payment of Death Benefit
	 	 	20	 
	 
	 	 	 	 
	ARTICLE 10 Beneficiary Designation
	 	 	20	 
	 
	 	 	 	 
	10.1 Beneficiary
	 	 	20	 
	10.2 Beneficiary Designation; Change; Spousal Consent
	 	 	21	 
	10.3 Acknowledgement
	 	 	21	 
	10.4 No Beneficiary Designation
	 	 	21	 
	10.5 Doubt as to Beneficiary
	 	 	21	 
	10.6 Discharge of Obligations
	 	 	21	 
	 
	 	 	 	 
	ARTICLE 11 Leave of Absence
	 	 	21	 
	 
	 	 	 	 
	11.1 Paid Leave of Absence
	 	 	21	 
	11.2 Unpaid Leave of Absence
	 	 	21	 
	11.3 Leaves Resulting in Separation from Service
	 	 	22	 
	 
	 	 	 	 
	ARTICLE 12 Termination of Plan, Amendment or Modification
	 	 	22	 
	 
	 	 	 	 
	12.1 Termination of Plan
	 	 	22	 
	12.2 Amendment
	 	 	23	 
	12.3 Plan Agreement
	 	 	23	 
	12.4 Effect of Payment
	 	 	23	 
	 
	 	 	 	 
	ARTICLE 13 Administration
	 	 	23	 
	 
	 	 	 	 
	13.1 Committee Duties
	 	 	23	 
	13.2 Administration Upon Change In Control
	 	 	24	 
	13.3 Agents
	 	 	24	 
	13.4 Binding Effect of Decisions
	 	 	24	 
	13.5 Indemnity of Committee
	 	 	24	 
	13.6 Employer Information
	 	 	24	 
	 
	 	 	 	 
	ARTICLE 14 Other Benefits and Agreements
	 	 	24	 
	 
	 	 	 	 
	14.1 Coordination with Other Benefits
	 	 	24	 
	 
	 	 	 	 
	ARTICLE 15 Claims Procedures
	 	 	25	 

-ii-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	 	 	 
	 	 	Page	 
	15.1 Presentation of Claim
	 	 	25	 
	15.2 Notification of Decision
	 	 	25	 
	15.3 Review of a Denied Claim
	 	 	25	 
	15.4 Decision on Review
	 	 	26	 
	15.5 Legal Action
	 	 	26	 
	 
	 	 	 	 
	ARTICLE 16 Trust
	 	 	26	 
	 
	 	 	 	 
	16.1 Establishment of the Trust
	 	 	26	 
	16.2 Interrelationship of the Plan and the Trust
	 	 	26	 
	16.3 Distributions From the Trust
	 	 	26	 
	 
	 	 	 	 
	ARTICLE 17 Miscellaneous
	 	 	27	 
	 
	 	 	 	 
	17.1 Status of Plan
	 	 	27	 
	17.2 Unsecured General Creditor
	 	 	27	 
	17.3 Employer’s Liability
	 	 	27	 
	17.4 Nonassignability
	 	 	27	 
	17.5 Not a Contract of Employment
	 	 	27	 
	17.6 Furnishing Information
	 	 	27	 
	17.7 Terms
	 	 	28	 
	17.8 Captions
	 	 	28	 
	17.9 Governing Law
	 	 	28	 
	17.10 Notice
	 	 	28	 
	17.11 Successors
	 	 	28	 
	17.12 Spouse’s Interest
	 	 	28	 
	17.13 Validity
	 	 	28	 
	17.14 Incompetent
	 	 	28	 
	17.15 Court Order
	 	 	29	 
	17.16 Distribution in the Event of Income Inclusion Under 409A
	 	 	29	 
	17.17 Deduction Limitation on Benefit Payments
	 	 	29	 
	17.18 Insurance
	 	 	29	 

-iii-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

NOVEN PHARMACEUTICALS, INC.

NONQUALIFIED DEFERRED COMPENSATION PLAN

Effective January 1, 2006

Amended and Restated September 15, 2006

Purpose

     The purpose of this Plan is to provide specified benefits to Directors and a select group of
management or highly compensated Employees who contribute materially to the continued growth,
development and future business success of Noven Pharmaceuticals, Inc., a Delaware corporation, and
its subsidiaries, if any, that sponsor this Plan. This Plan shall be unfunded for tax purposes and
for purposes of Title I of ERISA.

     The Plan is intended to comply with all applicable law, including Code Section 409A and
related Treasury guidance and Regulations, and shall be operated and interpreted in accordance with
this intention. This Plan was adopted effective January 1, 2006 and has been amended and restated
as of August 1, 2006 to reflect certain changes necessitated by Treasury Regulations promulgated
pursuant to Code Section 409A. Consistent with the foregoing, and in order to transition the Plan
to the requirements of Code Section 409A and related Treasury guidance and Regulations, the
Committee has made available, or will make available, to Participants certain transition relief
described more fully in Appendix A of this Plan, as permitted by Code Section 409A and related
Treasury guidance and Regulations.

ARTICLE 1

Definitions

     For the purposes of this Plan, unless otherwise clearly apparent from the context, the
following phrases or terms shall have the following indicated meanings:

	1.1	 	“Account Balance” shall mean, with respect to a Participant, an entry on the records of the
Employer equal to the sum of (i) the Deferral Account balance, (ii) the Company Contribution
Account balance, (iii) the Company Restoration Matching Account balance, and (iv) the
Restricted Stock Account balance. The Account Balance shall be a bookkeeping entry only and
shall be utilized solely as a device for the measurement and determination of the amounts to
be paid to a Participant, or his or her designated Beneficiary, pursuant to this Plan.
	 
	1.2	 	“Annual Deferral Amount” shall mean that portion of a Participant’s Base Salary, Bonus,
Director Fees and LTIP Amounts that a Participant defers in accordance with Article 3 for any
one Plan Year, without regard to whether such amounts are withheld and credited during such
Plan Year. In the event of a Participant’s Retirement, Disability, death or Termination of
Employment prior to the end of a Plan Year, such year’s Annual Deferral Amount shall be the
actual amount withheld prior to such event.
	 
	1.3	 	“Annual Installment Method” shall be an annual installment payment over the number of years
selected by the Participant in accordance with this Plan, calculated as follows: (i) for the
first annual installment, the Participant’s vested Account Balance shall be calculated as of
the close of business on or around the Participant’s Benefit Distribution Date, as determined
by the

-1-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	Committee in its sole discretion, and (ii) for remaining annual installments, the
Participant’s vested Account Balance shall be calculated on every anniversary of such
calculation date, as applicable. Each annual installment shall be calculated by multiplying
this balance by a fraction, the numerator of which is one and the denominator of which is the
remaining number of annual payments due the Participant. By way of example, if the
Participant elects a ten (10) year Annual Installment Method for the Retirement Benefit, the
first payment shall be 1/10 of the vested Account Balance, calculated as described in this
definition. The following year, the payment shall be 1/9 of the vested Account Balance,
calculated as described in this definition. Shares of Stock that shall be distributable from
the Restricted Stock Account shall be distributable in shares of actual Stock in the same
manner previously described. However, the Committee may, in its sole discretion, adjust the
annual installments in order to distribute whole shares of actual Stock.
	 
	1.4	 	“Base Salary” shall mean the annual cash compensation relating to services performed during
any calendar year, excluding distributions from nonqualified deferred compensation plans,
bonuses, commissions, overtime, fringe benefits, stock options, relocation expenses, incentive
payments, non-monetary awards, director fees and other fees, and automobile and other
allowances paid to a Participant for employment services rendered (whether or not such
allowances are included in the Employee’s gross income). Base Salary shall be calculated
before reduction for compensation voluntarily deferred or contributed by the Participant
pursuant to all qualified or nonqualified plans of any Employer and shall be calculated to
include amounts not otherwise included in the Participant’s gross income under Code Sections
125, 402(e)(3), 402(h), or 403(b) pursuant to plans established by any Employer; provided,
however, that all such amounts will be included in compensation only to the extent that had
there been no such plan, the amount would have been payable in cash to the Employee.
	 
	1.5	 	“Beneficiary” shall mean one or more persons, trusts, estates or other entities, designated
in accordance with Article 10, that are entitled to receive benefits under this Plan upon the
death of a Participant.
	 
	1.6	 	“Beneficiary Designation Form” shall mean the form established from time to time by the
Committee that a Participant completes, signs and returns to the Committee to designate one or
more Beneficiaries.
	 
	1.7	 	“Benefit Distribution Date” shall mean the date that triggers distribution of a Participant’s
vested Account Balance. A Participant’s Benefit Distribution Date shall be determined upon
the occurrence of any one of the following:

	 	(a)	 	If the Participant Retires, his or her Benefit Distribution Date shall be

	 	(i)	 	the last day of the six-month period immediately following the
date on which the Participant Retires if the Participant is a Key Employee, and
	 
	 	(ii)	 	for all other Participants, the date on which the Participant
Retires;
	 
	 	(iii)	 	provided, however, in the event the Participant changes
his or her Retirement Benefit election in accordance with Section 6.2(b), his or
her Benefit Distribution Date shall be postponed in accordance with Section
6.2(b); or

	 	(b)	 	If the Participant experiences a Termination of Employment, his or her Benefit
Distribution Date shall be

-2-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	(i)	 	the last day of the six-month period immediately following the
date on which the Participant experiences a Termination of Employment if the
Participant is a Key Employee, and
	 
	 	(ii)	 	for all other Participants, the date on which the Participant
experiences a Termination of Employment;
	 
	 	(iii)	 	provided, however, in the event the Participant changes
his or her Termination Benefit election in accordance with Section 7.2(b), his
or her Benefit Distribution Date shall be postponed in accordance with Section
7.2(b); or

	 	(c)	 	The date on which the Committee is provided with proof that is satisfactory to
the Committee of the Participant’s death, if the Participant dies prior to the complete
distribution of his or her vested Account Balance; or
	 
	 	(d)	 	The date on which the Participant becomes Disabled; or
	 
	 	(e)	 	The date on which the Company experiences a Change in Control, as determined by
the Committee in its sole discretion, if (i) the Participant has elected to receive a
Change in Control Benefit, as set forth in Section 5.1 below, and (ii) if a Change in
Control occurs prior to the Participant’s Termination of Employment, Retirement, death
or Disability.

	1.8	 	“Board” shall mean the board of directors of the Company.
	 
	1.9	 	“Bonus” shall mean any compensation, in addition to Base Salary and LTIP Amounts, earned by a
Participant for services rendered during a Plan Year, under any Employer’s annual bonus and
cash incentive plans, or other arrangement designated by the Committee, as further specified
on an Election Form.
	 
	1.10	 	“Change in Control” shall mean any “change in control event” as defined in accordance with
Code Section 409A and related Treasury guidance and Regulations.
	 
	1.11	 	“Change in Control Benefit” shall have the meaning set forth in Article 5.
	 
	1.12	 	“Claimant” shall have the meaning set forth in Section 15.1.
	 
	1.13	 	“Code” shall mean the Internal Revenue Code of 1986, as it may be amended from time to time.
	 
	1.14	 	“Committee” shall mean the committee described in Article 13.
	 
	1.15	 	“Company” shall mean Noven Pharmaceuticals, Inc., a Delaware corporation, and any successor
to all or substantially all of the Company’s assets or business.
	 
	1.16	 	“Company Contribution Account” shall mean (i) the sum of the Participant’s Company
Contribution Amounts, plus (ii) amounts credited or debited to the Participant’s Company
Contribution Account in accordance with this Plan, less (iii) all distributions made to the
Participant or his or her Beneficiary pursuant to this Plan that relate to the Participant’s
Company Contribution Account.
	 
	1.17	 	“Company Contribution Amount” shall mean, for any one Plan Year, the amount determined in
accordance with Section 3.5.
	 
	1.18	 	“Company Restoration Matching Account” shall mean (i) the sum of all of a Participant’s
Company Restoration Matching Amounts, plus (ii) amounts credited or debited to the
Participant’s Company Restoration Matching Account in accordance with this Plan, less (iii)
all

-3-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	distributions made to the Participant or his or her Beneficiary pursuant to this Plan that
relate to the Participant’s Company Restoration Matching Account.
	 
	1.19	 	“Company Restoration Matching Amount” shall mean, for any one Plan Year, the amount
determined in accordance with Section 3.6.
	 
	1.20	 	“Death Benefit” shall mean the benefit set forth in Article 9.
	 
	1.21	 	“Deferral Account” shall mean (i) the sum of all of a Participant’s Annual Deferral Amounts,
plus (ii) amounts credited or debited to the Participant’s Deferral Account in accordance with
this Plan, less (iii) all distributions made to the Participant or his or her Beneficiary
pursuant to this Plan that relate to his or her Deferral Account.
	 
	1.22	 	“Director” shall mean any elected or appointed member of the board of directors of any
Employer.
	 
	1.23	 	“Director Fees” shall mean the annual fees payable in cash that are earned by a Director from
any Employer, including retainer fees and meetings fees, as compensation for serving on the
board of directors.
	 
	1.24	 	“Disability” or “Disabled” shall mean that a Participant is (i) unable to engage in any
substantial gainful activity by reason of any medically determinable physical or mental
impairment which can be expected to result in death or can be expected to last for a
continuous period of not less than 12 months, or (ii) by reason of any medically determinable
physical or mental impairment which can be expected to result in death or can be expected to
last for a continuous period of not less than 12 months, receiving income replacement benefits
for a period of not less than 3 months under an accident or health plan covering employees of
the Participant’s Employer. For purposes of this Plan, a Participant shall be deemed Disabled
if determined to be totally disabled by the Social Security Administration, or if determined
to be disabled in accordance with the applicable disability insurance program of such
Participant’s Employer, provided that the definition of “disability” applied under such
disability insurance program complies with the requirements in the preceding sentence.
	 
	1.25	 	“Disability Benefit” shall mean the benefit set forth in Article 8.
	 
	1.26	 	“Election Form” shall mean the form, which may be in electronic format, established from time
to time by the Committee that a Participant completes, signs and returns to the Committee to
make an election under the Plan.
	 
	1.27	 	“Employee” shall mean a person who is an employee of any Employer.
	 
	1.28	 	“Employer(s)” shall mean the Company and/or any of its subsidiaries (now in existence or
hereafter formed or acquired) that have been selected by the Board to participate in the Plan
and have adopted the Plan as a sponsor.
	 
	1.29	 	“ERISA” shall mean the Employee Retirement Income Security Act of 1974, as it may be amended
from time to time.
	 
	1.30	 	“401(k) Plan” shall mean, with respect to an Employer, a plan qualified under Code Section
401(a) that contains a cash or deferral arrangement described in Code Section 401(k), adopted
by the Employer, as it may be amended from time to time, or any successor thereto.

-4-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	1.31	 	“Key Employee” shall mean any Participant who is a “key employee” (as defined in Code Section
416(i) without regard to paragraph (5) thereof) of an Employer whose stock is publicly traded
on an established securities market or otherwise, as determined by the Committee based upon
the 12-month period ending on each December 31st (such 12-month period is referred
to below as the “identification period”). All Participants who are determined to be key
employees under Code Section 416(i) (without regard to paragraph (5) thereof) during the
identification period shall be treated as Key Employees for purposes of the Plan during the
12-month period that begins on the first day of the 4th month following the close
of such identification period.
	 
	1.32	 	“LTIP Amounts” shall mean any portion of the cash compensation attributable to a Plan Year
that is earned by a Participant as an Employee under any Employer’s long-term incentive plan
or any other long-term incentive arrangement designated by the Committee.
	 
	1.33	 	“Participant” shall mean any Employee or Director (i) who is selected to participate in the
Plan, (ii) who submits an executed Plan Agreement, Election Form and Beneficiary Designation
Form, which are accepted by the Committee, and (iii) whose Plan Agreement has not terminated.
	 
	1.34	 	“Plan” shall mean the Noven Pharmaceuticals, Inc. Nonqualified Deferred Compensation Plan,
which shall be evidenced by this instrument and by each Plan Agreement, as they may be amended
from time to time.
	 
	1.35	 	“Plan Agreement” shall mean a written agreement, as may be amended from time to time, which
is entered into by and between an Employer and a Participant. Each Plan Agreement executed by
a Participant and the Participant’s Employer shall provide for the entire benefit to which
such Participant is entitled under the Plan; should there be more than one Plan Agreement, the
Plan Agreement bearing the latest date of acceptance by the Employer shall supersede all
previous Plan Agreements in their entirety and shall govern such entitlement. The terms of
any Plan Agreement may be different for any Participant, and any Plan Agreement may provide
additional benefits not set forth in the Plan or limit the benefits otherwise provided under
the Plan; provided, however, that any such additional benefits or benefit limitations must be
agreed to by both the Employer and the Participant.
	 
	1.36	 	“Plan Year” shall mean a period beginning on January 1 of each calendar year and continuing
through December 31 of such calendar year.
	 
	1.37	 	“Restricted Stock” shall mean rights to receive unvested shares of restricted stock selected
by the Committee in its sole discretion and awarded to the Participant under any Noven
Pharmaceuticals, Inc. stock incentive plan or director compensation program.
	 
	1.38	 	“Restricted Stock Account” shall mean the aggregate value, measured on any given date, of (i)
the number of shares of Restricted Stock deferred by a Participant as a result of all
Restricted Stock Amounts, plus (ii) the number of additional shares credited to a
Participant’s Restricted Stock Account as a result of the deemed reinvestment of dividends in
accordance with this Plan, less (iii) the number of shares of Restricted Stock previously
distributed to the Participant or his or her Beneficiary pursuant to this Plan, subject in
each case to any adjustments to the number of such shares determined by the Committee with
respect to the Noven Pharmaceuticals, Inc. Stock Unit Fund pursuant to Section 3.10. This
portion of the Participant’s Account Balance shall only be distributable in actual shares of
Stock.

-5-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	1.39	 	“Restricted Stock Amount” shall mean, with respect to a Participant for any one Plan Year,
the amount of Restricted Stock deferred in accordance with Section 3.7 of this Plan,
calculated using the closing price of Stock at the end of the business day closest to the date
such Restricted Stock would otherwise vest (and/or all restrictions on such Restricted Stock
would have lapsed), but for the election to defer. In the event of a Participant’s
Retirement, Termination of Employment, Disability, or death prior to the end of a Plan Year,
such year’s Restricted Stock Amount shall be the actual amount withheld prior to such event.
	 
	1.40	 	“Retirement”, “Retire(s)” or “Retired” shall mean, with respect to an Employee, separation
from service with all Employers for any reason other than death or Disability, as determined
in accordance with Code Section 409A and related Treasury guidance and Regulations, on or
after the earlier of the attainment of (a) age sixty-five (65) or (b) age fifty-five (55) with
five (5) Years of Service; and shall mean with respect to a Director who is not an Employee,
separation from service as a Director with all Employers. If a Participant is both an
Employee and a Director, Retirement shall not occur until he or she Retires as both an
Employee and a Director.
	 
	1.41	 	“Retirement Benefit” shall mean the benefit set forth in Article 6.
	 
	1.42	 	“Scheduled Distribution” shall mean the distribution set forth in Section 4.1.
	 
	1.43	 	“Stock” shall mean Noven Pharmaceuticals, Inc. common stock, $0.0001 par value, or any other
equity securities of the Company designated by the Committee.
	 
	1.44	 	“Terminate the Plan”, “Termination of the Plan” shall mean a determination by an Employer’s
board of directors that (i) all of its Participants shall no longer be eligible to
participate in the Plan, (ii) no new deferral elections for such Participants shall be
permitted, and (iii) such Participants shall no longer be eligible to receive company
contributions under this Plan.
	 
	1.45	 	“Termination Benefit” shall mean the benefit set forth in Article 7.
	 
	1.46	 	“Termination of Employment” shall mean the separation from service with all Employers,
voluntarily or involuntarily, for any reason other than Retirement, Disability or death, as
determined in accordance with Code Section 409A and related Treasury guidance and Regulations.
If a Participant is both an Employee and a Director, a Termination of Employment shall occur
only upon the termination of the last position held. A Participant will not have a Termination
of Employment unless the Participant is not employed by the Company, a Subsidiary, or any
other member of the Controlled Group of Corporations as defined under Code Section 414(b)
(dealing with controlled groups of corporations) and Code Section 414(c), regardless of the
reason for the termination of employment.
	 
	1.47	 	“Trust” shall mean one or more trusts established by the Company in accordance with Article
16.
	 
	1.48	 	“Unforeseeable Emergency” shall mean a severe financial hardship of the Participant or his or
her Beneficiary resulting from (i) an illness or accident of the Participant or Beneficiary,
the Participant’s or Beneficiary’s spouse, or the Participant’s or Beneficiary’s dependent (as
defined in Code Section 152(a)), (ii) a loss of the Participant’s or Beneficiary’s property
due to casualty, or (iii) such other similar extraordinary and unforeseeable circumstances
arising as a result of events beyond the control of the Participant or the Participant’s
Beneficiary, all as determined in the sole discretion of the Committee.

-6-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	1.49	 	“Years of Service” shall mean the total number of full years in which a Participant has been
employed by one or more Employers. For purposes of this definition, a year of employment
shall be a 365 day period (or 366 day period in the case of a leap year) that, for the first
year of employment, commences on the Employee’s date of hiring and that, for any subsequent
year, commences on an anniversary of that hiring date. The Committee shall make a
determination as to whether any partial year of employment shall be counted as a Year of
Service.

ARTICLE 2

Selection, Enrollment, Eligibility

	2.1	 	Selection by Committee. Participation in the Plan shall be limited to Directors and,
as determined by the Committee in its sole discretion, a select group of management or highly
compensated Employees. From that group, the Committee shall select, in its sole discretion,
those individuals who may actually participate in this Plan.
	 
	2.2	 	Enrollment and Eligibility Requirements; Commencement of Participation.

	 	(a)	 	As a condition to participation, each Director or selected Employee who is
eligible to participate in the Plan effective as of the first day of a Plan Year shall
complete, execute and return to the Committee a Plan Agreement, an Election Form and a
Beneficiary Designation Form, prior to the first day of such Plan Year, or such other
earlier deadline as may be established by the Committee in its sole discretion. In
addition, the Committee shall establish from time to time such other enrollment
requirements as it determines, in its sole discretion, are necessary.
	 
	 	(b)	 	A Director or selected Employee who first becomes eligible to participate in
this Plan after the first day of a Plan Year must complete, execute and return to the
Committee a Plan Agreement, an Election Form, and a Beneficiary Designation Form within
thirty (30) days after he or she first becomes eligible to participate in the Plan, or
within such other earlier deadline as may be established by the Committee, in its sole
discretion, in order to participate for that Plan Year. In such event, such person’s
participation in this Plan shall not commence earlier than the date determined by the
Committee pursuant to Section 2.2(c) and such person shall not be permitted to defer
under this Plan any portion of his or her Base Salary, Bonus, LTIP Amounts, Restricted
Stock Amounts and/or Director Fees that are paid with respect to services performed
prior to his or her
participation commencement date, except to the extent permissible under Code Section
409A and related Treasury guidance or Regulations.
	 
	 	(c)	 	Each Director or selected Employee who is eligible to participate in the Plan
shall commence participation in the Plan on the date that the Committee determines, in
its sole discretion, that the Director or Employee has met all enrollment requirements
set forth in this Plan and required by the Committee, including returning all required
documents to the Committee within the specified time period. Notwithstanding the
foregoing, the Committee shall process such Participant’s deferral election as soon as
administratively practicable after such deferral election is submitted to and accepted
by the Committee.

-7-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	(d)	 	If a Director or an Employee fails to meet all requirements contained in this
Section 2.2 within the period required, that Director or Employee shall not be eligible
to participate in the Plan during such Plan Year.

ARTICLE 3

Deferral Commitments/Company Contribution Amounts/

Company Restoration Matching Amounts/Restricted Stock Amounts/ Vesting/Crediting/Taxes

	3.1	 	Minimum Deferrals.

	 	(a)	 	Annual Deferral Amount. For each Plan Year, a Participant may elect to
defer, as his or her Annual Deferral Amount, Base Salary, Bonus, LTIP Amounts and/or
Director Fees in the following minimum amounts for each deferral elected:

	 	 	 	 	 
	Deferral	 	Minimum Amount
	Base Salary, Bonus
and/or LTIP Amounts
	 	$	4,000 aggregate
	Director Fees
	 	$	4,000

	 	 	 	If the Committee determines, in its sole discretion, prior to the beginning of a Plan
Year that a Participant has made an election for less than the stated minimum
amounts, or if no election is made, the amount deferred shall be zero. If the
Committee determines, in its sole discretion, at any time after the beginning of a
Plan Year that a Participant has deferred less than the stated minimum amounts for
that Plan Year, any amount credited to the Participant’s Account Balance as the
Annual Deferral Amount for that Plan Year shall be distributed to the Participant
within sixty (60) days after the last day of the Plan Year in which the Committee
determination was made.
	 
	 	(b)	 	Restricted Stock Amount. For each grant of Restricted Stock, a
Participant may elect to defer, as his or her Restricted Stock Amount, Restricted Stock
in the following minimum percentage:

	 	 	 	 	 
	Deferral	 	Minimum Percentage
	Restricted Stock
	 	 	0	%

	 	 	 	If no election is made, the percentage deferred shall be zero.
	 
	 	(c)	 	Short Plan Year. Notwithstanding the foregoing, if a Participant first
becomes a Participant after the first day of a Plan Year, the minimum Annual Deferral
Amount shall be an amount equal to the minimum set forth above, multiplied by a
fraction, the numerator of which is the number of complete months remaining in the Plan
Year and the denominator of which is 12.

	3.2	 	Maximum Deferral.

	 	(a)	 	Annual Deferral Amount. For each Plan Year, a Participant may elect to
defer, as his or her Annual Deferral Amount, Base Salary, Bonus, LTIP Amounts and/or
Director Fees up to the following maximum percentages for each deferral elected:

-8-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	 	 	 
	Deferral	 	Maximum Percentage
	Base Salary
	 	 	75	%
	Bonus
	 	 	100	%
	LTIP Amounts
	 	 	100	%
	Director Fees
	 	 	100	%

	 	(b)	 	Restricted Stock Amount. For each grant of Restricted Stock, a
Participant may elect to defer, as his or her Restricted Stock Amount, Restricted Stock
in the following maximum percentage:

	 	 	 	 	 
	Deferral	 	Maximum Percentage
	Restricted Stock
	 	 	100	%

	 	(c)	 	Short Plan Year. Notwithstanding the foregoing, if a Participant first
becomes a Participant after the first day of a Plan Year, the maximum Annual Deferral
Amount shall be limited to the amount of compensation not yet earned by the Participant
as of the date the Participant submits a Plan Agreement and Election Form to the
Committee for acceptance, except to the extent permissible under Code Section 409A and
related Treasury guidance or Regulations. For compensation that is earned based upon a
specified performance period, the Participant’s deferral election will apply to the
portion of such compensation that is equal to (i) the total amount of compensation for
the performance period, multiplied by (ii) a fraction, the numerator of which is the
number of days remaining in the service period after the Participant’s deferral
election is made, and the denominator of which is the total number of days in the
performance period.

	3.3	 	Election to Defer; Effect of Election Form.

	 	(a)	 	First Plan Year. In connection with a Participant’s commencement of
participation in the Plan, the Participant shall make an irrevocable deferral election
for the Plan Year in which the Participant commences participation in the Plan, along
with such other elections as the Committee deems necessary or desirable under the Plan.
For these elections to be valid, the Election Form must be completed and signed by the
Participant,
timely delivered to the Committee (in accordance with Section 2.2 above) and accepted
by the Committee.
	 
	 	(b)	 	General Timing Rule for Deferral Elections in Subsequent Plan Years.
For each succeeding Plan Year, a Participant may elect to defer Base Salary, Bonus,
Director Fees and LTIP Amounts, and make such other elections as the Committee deems
necessary or desirable under the Plan by timely delivering a new Election Form to the
Committee, in accordance with its rules and procedures, no later than (i) the December
31st preceding the Plan Year in which such compensation is earned, or (ii)
such other deadline established by the Committee in accordance with the requirements of
Code Section 409A and related Treasury guidance or Regulations.
	 
	 	 	 	Any deferral election(s) made in accordance with this Section 3.3(b) shall be
irrevocable; provided, however, that if the Committee requires Participants to make a
deferral election

-9-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	 	for “performance-based compensation” by the deadline(s) described
above, it may, in its sole discretion, and in accordance with Code Section 409A and
related Treasury guidance or Regulations, permit a Participant to subsequently change
his or her deferral election for such compensation by submitting an Election Form to
the Committee no later than the deadline established by the Committee pursuant to
Section 3.3(d) below.
	 
	 	(c)	 	Restricted Stock Deferral. For an election to defer Restricted Stock
to be valid, an Election Form must be completed and signed by the Participant with
respect to such Restricted Stock. Such Election Form must be timely delivered to the
Committee and accepted by the Committee no later than (i) the end of the calendar year
preceding the Plan Year during which such Restricted Stock may be initially granted to
the Participant under the terms of the applicable Noven Pharmaceuticals, Inc. stock
incentive plan or director compensation program, or (ii) such other deadline
established by the Committee in accordance with the requirements of Code Section 409A
and related Treasury guidance or Regulations, including, without limitation, such
deadline as may be applicable under Section 3.3(d) or Section 3.3(e) below.
	 
	 	(d)	 	Performance-Based Compensation. Notwithstanding the foregoing, the
Committee may, in its sole discretion, determine that an irrevocable deferral election
pertaining to “performance-based compensation” based on services performed over a
period of at least twelve (12) months, may be made by timely delivering an Election
Form to the Committee, in accordance with its rules and procedures, no later than six
(6) months before the end of the performance service period. “Performance-based
compensation” shall be compensation, the payment or amount of which is contingent on
pre-established organizational or individual performance criteria, which satisfies the
requirements of Code Section 409A and related Treasury guidance or Regulations. In
order to be eligible to make a deferral election for performance-based compensation, a
Participant must perform services continuously from a date no later than the date upon
which the performance criteria for such compensation are established through the date
upon which the Participant makes a deferral election for such compensation. In no
event shall an election to defer performance-based compensation be permitted after such
compensation has become both substantially certain to be paid and readily
ascertainable.
	 
	 	(e)	 	Compensation Subject to Risk of Forfeiture. With respect to
compensation (i) to which a Participant has a legally binding right to payment in a
subsequent year, and (ii) that is subject to a forfeiture condition requiring the
Participant’s continued services for a period of at least twelve (12) months from the
date the Participant obtains the legally binding right, the Committee may, in its sole
discretion, determine that an irrevocable deferral election for such compensation may
be made by timely delivering an Election Form to the Committee in accordance with its
rules and procedures, no later than the 30th day after the Participant obtains the
legally binding right to the compensation, provided that the election is made at least
twelve (12) months in advance of the earliest date at which the forfeiture condition
could lapse.

	3.4	 	Withholding and Crediting of Annual Deferral Amounts. For each Plan Year, the Base
Salary portion of the Annual Deferral Amount shall be withheld from each regularly scheduled
Base Salary payroll in equal amounts, as adjusted from time to time for increases and
decreases in Base Salary. The Bonus, LTIP Amounts and/or Director Fees portion of the Annual
Deferral

-10-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	Amount shall be withheld at the time the Bonus, LTIP Amounts or Director Fees are or
otherwise would be paid to the Participant, whether or not this occurs during the Plan Year
itself. Annual Deferral Amounts shall be credited to a Participant’s Deferral Account at the
time such amounts would otherwise have been paid to the Participant.

	3.5	 	Company Contribution Amount.

	 	(a)	 	For each Plan Year, an Employer may be required to credit amounts to a
Participant’s Company Contribution Account in accordance with employment or other
agreements entered into between the Participant and the Employer. Such amounts shall
be credited on the date or dates prescribed by such agreements.
	 
	 	(b)	 	For each Plan Year, an Employer, in its sole discretion, may, but is not
required to, credit any amount it desires to any Participant’s Company Contribution
Account under this Plan, which amount shall be for that Participant the Company
Contribution Amount for that Plan Year. The amount so credited to a Participant may be
smaller or larger than the amount credited to any other Participant, and the amount
credited to any Participant for a Plan Year may be zero, even though one or more other
Participants receive a Company Contribution Amount for that Plan Year. The Company
Contribution Amount described in this Section 3.5(b), if any, shall be credited on a
date or dates to be determined by the Committee, in its sole discretion.

	3.6	 	Company Restoration Matching Amount. A Participant’s Company Restoration Matching
Amount for any Plan Year shall be an amount determined by the Committee, in its sole
discretion, to make up for certain limits applicable to the 401(k) Plan or other qualified
plan for such Plan Year, as identified by the Committee, or for such other purposes as
determined by the Committee in its sole discretion. The amount so credited to a Participant
under this Plan for any Plan Year (i) may be smaller or larger than the amount credited to any
other Participant, and (ii) may differ from the amount credited to such Participant in the
preceding Plan Year. The Participant’s Company Restoration Matching Amount, if any, shall be
credited on a date or dates to be determined by the Committee, in its sole discretion.
	 
	3.7	 	Restricted Stock Amounts. Subject to any terms and conditions imposed by the
Committee, a Participant may elect to defer Restricted Stock under the Plan, which amount
shall be for that Participant the Restricted Stock Amount for that Plan Year. The portion of
any Restricted Stock deferred shall, at the time the Restricted Stock would otherwise vest
(and/or all restrictions on such Restricted Stock would have lapsed) under the terms of the
applicable Noven Pharmaceuticals, Inc. stock incentive plan or director compensation program,
but for the election to defer, be reflected on the books of the Company as an unfunded,
unsecured promise to deliver to the Participant a specific number of actual shares of Stock in
the future.
	 
	3.8	 	Crediting of Amounts after Benefit Distribution. Notwithstanding any provision in
this Plan to the contrary, should the complete distribution of a Participant’s vested Account
Balance occur prior to the date on which any portion of (i) the Annual Deferral Amount that a
Participant has elected to defer in accordance with Section 3.3, (ii) the Company Contribution
Amount, (iii) the Company Restoration Matching Amount, or (iv) the Restricted Stock Amount,
would otherwise be credited to the Participant’s Account Balance, such amounts shall not be
credited to the Participant’s Account Balance, but shall be paid to the Participant in a
manner determined by the Committee, in its sole discretion.

-11-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	3.9	 	Vesting.

	 	(a)	 	A Participant shall at all times be 100% vested in his or her Deferral Account
and Restricted Stock Account.
	 
	 	(b)	 	A Participant shall be vested in his or her Company Contribution Account in
accordance with the vesting schedule(s) set forth in his or her Plan Agreement,
employment agreement or any other agreement entered into between the Participant and
his or her Employer. If not addressed in such agreements, a Participant shall vest in
his or her Company Contribution Account in accordance with a vesting schedule declared
by the Committee in its sole discretion.
	 
	 	(c)	 	A Participant shall be vested in his or her Company Restoration Matching
Account only to the extent that the Participant would be vested in such amounts under
the provisions of the 401(k) Plan, as determined by the Committee in its sole
discretion.
	 
	 	(d)	 	Notwithstanding anything to the contrary contained in this Section 3.9, in the
event of a Change in Control, or upon a Participant’s Retirement, death while employed
by an Employer, or Disability, a Participant’s Company Contribution Account and Company
Restoration Matching Account shall immediately become 100% vested (if it is not already
vested in accordance with the above vesting schedules).
	 
	 	(e)	 	Notwithstanding subsection 3.9(d) above, the vesting schedule for a
Participant’s Company Contribution Account and Company Restoration Matching Account
shall not be accelerated upon a Change in Control to the extent that the Committee
determines that such acceleration would cause the deduction limitations of Section 280G
of the Code to become effective. In the event that all of a Participant’s Company
Contribution Account and/or Company Restoration Matching Account is not vested pursuant
to such a
determination, the Participant may request independent verification of the
Committee’s calculations with respect to the application of Section 280G. In such
case, the Committee must provide to the Participant within ninety (90) days of such a
request an opinion from a nationally recognized accounting firm selected by the
Participant (the “Accounting Firm”). The opinion shall state the Accounting Firm’s
opinion that any limitation in the vested percentage hereunder is necessary to avoid
the limits of Section 280G and contain supporting calculations. The cost of such
opinion shall be paid for by the Company.
	 
	 	(f)	 	Section 3.9(e) shall not prevent the acceleration of the vesting schedule
applicable to a Participant’s Company Contribution Account and/or Company Restoration
Matching Account if such Participant is entitled to a “gross-up” payment, to eliminate
the effect of the Code section 4999 excise tax, pursuant to his or her employment
agreement or other agreement entered into between such Participant and the Employer.

-12-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	3.10	 	Crediting/Debiting of Account Balances. In accordance with, and subject to, the
rules and procedures that are established from time to time by the Committee, in its sole
discretion, amounts shall be credited or debited to a Participant’s Account Balance in
accordance with the following rules:

	 	(a)	 	Measurement Funds. Subject to the restrictions found in Section
3.10(c) below, the Participant may elect one or more of the measurement funds selected
by the Committee, in its sole discretion, which are based on certain mutual funds (the
“Measurement Funds”), for the purpose of crediting or debiting additional amounts to
his or her Account Balance. As necessary, the Committee may, in its sole discretion,
discontinue, substitute or add a Measurement Fund. Each such action will take effect
as of the first day of the first calendar quarter that begins at least thirty (30) days
after the day on which the Committee gives Participants advance written notice of such
change.
	 
	 	(b)	 	Election of Measurement Funds. Subject to the restrictions found in
Section 3.10(c) below, a Participant in connection with his or her initial deferral
election in accordance with Section 3.3(a) above, shall elect, on the Election Form,
one or more Measurement Fund(s) (as described in Section 3.10(a) above) to be used as a
guide for the Committee to determine the amounts to be credited or debited to his or
her Account Balance. If a Participant does not elect any of the Measurement Funds
described in the previous sentence, the Participant’s Account Balance shall be credited
or debited using the lowest-risk Measurement Fund, as determined by the Committee, in
its sole discretion. Subject to the restrictions found in Section 3.10(c) below, the
Participant may (but is not required to) elect, by submitting an Election Form to the
Committee that is accepted by the Committee, to add or delete one or more Measurement
Fund(s) to be used to determine the amounts to be credited or debited to his or her
Account Balance, or to change the portion of his or her Account Balance that is tied to
each previously or newly elected Measurement Fund. If an election is made in
accordance with the previous sentence, it shall apply as of the first business day
deemed reasonably practicable by the Committee, in its sole discretion, and shall
continue thereafter for each subsequent day in which the Participant participates in
the Plan, unless changed in accordance with the previous sentence. Notwithstanding the
foregoing, the Committee, in its sole discretion, may impose limitations on the
frequency with which one or more of the Measurement Funds
elected in accordance with this Section may be added or deleted by such Participant;
furthermore, the Committee in its sole discretion, may impose limitations on the
frequency with which the Participant may change the portion of his or her Account
Balance tied to each previously or newly elected Measurement Fund. In accordance
with Section 3.10(f), no amounts from a Participant’s Account balance are invested in
the Measurement Fund selected by a Participant, but merely used as a guide for the
Committee to debit or credit earnings for each Participant’s Account Balance.
	 
	 	(c)	 	Noven Pharmaceuticals, Inc. Stock Unit Fund.

	 	(i)	 	A Participant’s Restricted Stock Account will be automatically
and irrevocably allocated to the Noven Pharmaceuticals, Inc. Stock Unit Fund
Measurement Fund. Participants may not select any other Measurement Fund to be
used to determine the amounts to be credited or debited to their Restricted
Stock Account. Furthermore, no other portion of the Participant’s Account
Balance can be either

-13-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	 	initially allocated or re-allocated to the Noven
Pharmaceuticals, Inc. Stock Unit Fund. Amounts allocated to the Noven
Pharmaceuticals, Inc. Stock Unit Fund shall only be distributable in actual
 shares of Stock.
	 
	 	(ii)	 	Any stock dividends, cash dividends or other non-cash dividends
that would have been payable on the Stock credited to a Participant’s Account
Balance shall be credited to the Participant’s Account Balance in the form of
additional shares of Stock and shall automatically and irrevocably be deemed to
be re-invested in the Noven Pharmaceuticals, Inc. Stock Unit Fund until such
amounts are distributed to the Participant. The number of shares credited to
the Participant for a particular stock dividend shall be equal to (a) the number
of shares of Stock credited to the Participant’s Account Balance as of the
payment date for such dividend in respect of each share of Stock, multiplied by
(b) the number of additional or fractional shares of Stock actually paid as a
dividend in respect of each share of Stock. The number of shares credited to
the Participant for a particular cash dividend or other non-cash dividend shall
be equal to (a) the number of shares of Stock credited to the Participant’s
Account Balance as of the payment date for such dividend in respect of each
share of Stock, multiplied by (b) the fair market value of the dividend, divided
by (c) the “fair market value” of the Stock on the payment date for such
dividend.
	 
	 	(iii)	 	The number of shares of Stock credited to the Participant’s
Account Balance may be adjusted by the Committee, in its sole discretion, to
prevent dilution or enlargement of Participants’ rights with respect to the
portion of his or her Account Balance allocated to the Noven Pharmaceuticals,
Inc. Stock Unit Fund in the event of any reorganization, reclassification, stock
split, or other unusual corporate transaction or event which affects the value
of the Stock, provided that any such adjustment shall be made taking into
account any crediting of shares of Stock to the Participant under Section 3.10.
	 
	 	(iv)	 	For purposes of this Section 3.10(c), the fair market value of
the Stock shall be, in the event the Stock is traded on a recognized securities
exchange or quoted by the National Association of Securities Dealers Automated
Quotations on National
Market Issues, an amount equal to the closing price of the Stock on such
exchange or such quotation on the date set for valuation or, if no sales of
Stock were made on said exchange or so quoted on that date, the closing price
of the Stock on the next preceding day on which sales were made on such
exchange or quotations; or, if the Stock is not so traded or quoted, that
value determined, in its sole discretion, by the Committee in compliance with
Section 409A.

	 	(d)	 	Proportionate Allocation. In making any election described in Section
3.10(b) above, the Participant shall specify on the Election Form, in increments of one
percent (1%), the percentage of his or her Account Balance or Measurement Fund, as
applicable, to be allocated/reallocated.
	 
	 	(e)	 	Crediting or Debiting Method. The performance of each Measurement Fund
(either positive or negative) will be determined on a daily basis based on the manner
in which

-14-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	 	such Participant’s Account Balance has been hypothetically allocated among the
Measurement Funds by the Participant.
	 
	 	(f)	 	No Actual Investment. Notwithstanding any other provision of this Plan
that may be interpreted to the contrary, the Measurement Funds are to be used for
measurement purposes only, and a Participant’s election of any such Measurement Fund,
the allocation of his or her Account Balance thereto, the calculation of additional
amounts and the crediting or debiting of such amounts to a Participant’s Account
Balance shall not be considered or construed in any manner as an actual
investment of his or her Account Balance in any such Measurement Fund. In the event
that the Company or the Trustee (as that term is defined in the Trust), in its own
discretion, decides to invest funds in any or all of the investments on which the
Measurement Funds are based, no Participant shall have any rights in or to such
investments themselves. Without limiting the foregoing, a Participant’s Account
Balance shall at all times be a bookkeeping entry only and shall not represent any
investment made on his or her behalf by the Company or the Trust; the Participant shall
at all times remain an unsecured creditor of the Company.

	3.11	 	FICA and Other Taxes.

	 	(a)	 	Annual Deferral Amounts. For each Plan Year in which an Annual
Deferral Amount is being withheld from a Participant, the Participant’s Employer(s)
shall withhold from that portion of the Participant’s Base Salary, Bonus and/or LTIP
Amounts that is not being deferred, in a manner determined by the Employer(s), the
Participant’s share of FICA and other employment taxes on such Annual Deferral Amount.
If necessary, the Committee may reduce the Annual Deferral Amount in order to comply
with this Section 3.11.
	 
	 	(b)	 	Company Restoration Matching Account and Company Contribution Account.
When a Participant becomes vested in a portion of his or her Company Restoration
Matching Account and/or Company Contribution Account, the Participant’s Employer(s)
shall withhold from that portion of the Participant’s Base Salary, Bonus and/or LTIP
Amounts that is not deferred, in a manner determined by the Employer(s), the
Participant’s share of FICA and other employment taxes on such Company Restoration
Matching Amount and/or Company Contribution Amount. If necessary, the Committee may
reduce the vested portion of the Participant’s Company Restoration Matching
Account or Company Contribution Account, as applicable, in order to comply with this
Section 3.11.
	 
	 	(c)	 	Restricted Stock Amounts. For each Plan Year in which a Restricted
Stock Amount is being first withheld from an Employee Participant, the Participant’s
Employer(s) shall withhold from that portion of the Participant’s Base Salary, Bonus,
LTIP Amounts and/or Restricted Stock that are not being deferred, in a manner
determined by the Employer(s), the Participant’s share of FICA and other employment
taxes on such Restricted Stock Amount. If necessary, the Committee may reduce the
Restricted Stock Amount in order to comply with this Section 3.11.
	 
	 	(d)	 	Distributions. The Participant’s Employer(s), or the trustee of the
Trust, shall withhold from any payments made to a Participant under this Plan all
federal, state and local income, employment and other taxes required to be withheld by
the Employer(s), or the 

-15-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	 	trustee of the Trust, in connection with such payments, in
amounts and in a manner to be determined in the sole discretion of the Employer(s) and
the trustee of the Trust.

ARTICLE 4

 Scheduled Distribution; Unforeseeable Emergencies 

	4.1	 	Scheduled Distribution. In connection with each election to defer an Annual Deferral
Amount, a Participant may irrevocably elect to receive a Scheduled Distribution, in the form
of a lump sum payment, from the Plan with respect to all or a portion of the Annual Deferral
Amount. The Scheduled Distribution shall be a lump sum payment in an amount that is equal to
the portion of the Annual Deferral Amount the Participant elected to have distributed as a
Scheduled Distribution, plus amounts credited or debited in the manner provided in Section
3.10 above on that amount, calculated as of the close of business on or around the date on
which the Scheduled Distribution becomes payable, as determined by the Committee in its sole
discretion. Subject to the other terms and conditions of this Plan, each Scheduled
Distribution elected shall be paid out during a sixty (60) day period commencing immediately
after the first day of any Plan Year designated by the Participant (the “Scheduled
Distribution Date”). The Plan Year designated by the Participant must be at least two (2)
Plan Years after the end of the Plan Year to which the Participant’s deferral election
described in Section 3.3 relates, unless otherwise provided on an Election Form approved by
the Committee in its sole discretion. By way of example, if a Scheduled Distribution is
elected for Annual Deferral Amounts that are earned in the Plan Year commencing January 1,
2006, the earliest Scheduled Distribution Date that may be designated by a Participant would
be January 1, 2009, and the Scheduled Distribution would become payable during the sixty (60)
day period commencing immediately after such Scheduled Distribution Date.

	4.2	 	Postponing Scheduled Distributions. A Participant may elect to postpone a Scheduled
Distribution described in Section 4.1 above, and have such amount paid out during a sixty (60)
day period commencing immediately after an allowable alternative distribution date designated
by the Participant in accordance with this Section 4.2. In order to make this election, the
Participant must submit a new Scheduled Distribution Election Form to the Committee in
accordance with the following criteria:

	 	(a)	 	Such Scheduled Distribution Election Form must be submitted to and accepted by
the Committee in its sole discretion at least twelve (12) months prior to the
Participant’s previously designated Scheduled Distribution Date;
	 
	 	(b)	 	The new Scheduled Distribution Date selected by the Participant must be the
first day of a Plan Year, and must be at least five years after the previously
designated Scheduled Distribution Date; and
	 
	 	(c)	 	The election of the new Scheduled Distribution Date shall have no effect until
at least twelve (12) months after the date on which the election is made.

	4.3	 	Other Benefits Take Precedence Over Scheduled Distributions. Should a Benefit
Distribution Date occur that triggers a benefit under Articles 5, 6, 7, 8, or 9, any Annual
Deferral Amount that is subject to a Scheduled Distribution election under Section 4.1 shall
not be paid 

-16-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	in accordance with Section 4.1, but shall be paid in accordance with the other
applicable Article. Notwithstanding the foregoing, the Committee shall interpret this Section
4.3 in a manner that is consistent with Code Section 409A and other applicable tax law,
including but not limited to Treasury guidance and Regulations issued after the effective date
of this Plan.

	4.4	 	Unforeseeable Emergencies.

	 	(a)	 	If the Participant experiences an Unforeseeable Emergency, the Participant may
petition the Committee to receive a partial or full payout from the Plan, subject to
the provisions set forth below.
	 
	 	(b)	 	The payout, if any, from the Plan shall not exceed the lesser of (i) the
Participant’s vested Account Balance, excluding the portion of the Account Balance
attributable to the Restricted Stock Account, calculated as of the close of business on
or around the date on which the amount becomes payable, as determined by the Committee
in its sole discretion, or (ii) the amount necessary to satisfy the Unforeseeable
Emergency, plus amounts necessary to pay Federal, state, or local income taxes or
penalties reasonably anticipated as a result of the distribution. Notwithstanding the
foregoing, a Participant may not receive a payout from the Plan to the extent that the
Unforeseeable Emergency is or may be relieved (A) through reimbursement or compensation
by insurance or otherwise, (B) by liquidation of the Participant’s assets, to the
extent the liquidation of such assets would not itself cause severe financial hardship
or (C) by cessation of deferrals under this Plan.
	 
	 	(c)	 	If the Committee, in its sole discretion, approves a Participant’s petition for
payout from the Plan, the Participant shall receive a payout from the Plan within sixty
(60) days of the date of such approval, and the Participant’s deferrals under the Plan
shall be terminated as of the date of such approval.
	 
	 	(d)	 	In addition, a Participant’s deferral elections under this Plan shall be
terminated to the extent the Committee determines, in its sole discretion, that
termination of such Participant’s deferral elections is required pursuant to Treas.
Reg. §1.401(k)-1(d)(3) for the Participant to obtain a hardship distribution from an
Employer’s 401(k) Plan. If the Committee determines, in its sole discretion, that a
termination of the Participant’s
deferrals is required in accordance with the preceding sentence, the Participant’s
deferrals shall be terminated as soon as administratively practicable following the
date on which such determination is made.
	 
	 	(e)	 	Notwithstanding the foregoing, the Committee shall interpret all provisions
relating to a payout and/or termination of deferrals under this Section 4.4 in a manner
that is consistent with Code Section 409A and related Treasury guidance and
Regulations.

-17-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

ARTICLE 5

Change in Control Benefit 

	5.1	 	Change in Control Benefit. A Participant, in connection with his or her commencement
of participation in the Plan, shall irrevocably elect on an Election Form whether to (i)
receive a Change in Control Benefit upon the occurrence of a Change in Control, which shall be
equal to the Participant’s vested Account Balance, calculated as of the close of business on
or around the Participant’s Benefit Distribution Date, as determined by the Committee in its
sole discretion, or (ii) to have his or her Account Balance remain in the Plan upon the
occurrence of a Change in Control and to have his or her Account Balance remain subject to the
terms and conditions of the Plan. If a Participant does not make any election with respect to
the payment of the Change in Control Benefit, then such Participant’s Account Balance shall
remain in the Plan upon a Change in Control and shall be subject to the terms and conditions
of the Plan.

	5.2	 	Payment of Change in Control Benefit. The Change in Control Benefit, if any, shall
be paid to the Participant in a lump sum no later than sixty (60) days after the Participant’s
Benefit Distribution Date. Notwithstanding the foregoing, the Committee shall interpret all
provisions in this Plan relating to a Change in Control Benefit in a manner that is consistent
with Code Section 409A and related Treasury guidance and Regulations.

ARTICLE 6

Retirement Benefit

	6.1	 	Retirement Benefit. A Participant who Retires shall receive, as a Retirement
Benefit, his or her vested Account Balance, calculated as of the close of business on or
around the Participant’s Benefit Distribution Date, as determined by the Committee in its sole
discretion.

	6.2	 	Payment of Retirement Benefit.

	 	(a)	 	A Participant, in connection with his or her commencement of participation in
the Plan, shall elect on an Election Form to receive the Retirement Benefit in a lump
sum or pursuant to an Annual Installment Method of up to ten (10) years. If a
Participant does not make any election with respect to the payment of the Retirement
Benefit, then such Participant shall be deemed to have elected to receive the
Retirement Benefit in a lump sum.
	 
	 	(b)	 	A Participant may change the form of payment of the Retirement Benefit by
submitting an Election Form to the Committee in accordance with the following criteria:

	 	(i)	 	The election to modify the Retirement Benefit shall have no
effect until at least twelve (12) months after the date on which the election is
made; and
	 
	 	(ii)	 	The first Retirement Benefit payment shall be delayed at least
five (5) years from the Participant’s originally scheduled Benefit Distribution
Date described in Section 1.7(a).

	 	 	 	For purposes of applying the requirements above, the right to receive the Retirement
Benefit in installment payments shall be treated as the entitlement to a single
payment.

-18-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	 	The Committee shall interpret all provisions relating to changing the
Retirement Benefit election under this Section 6.2 in a manner that is consistent
with Code Section 409A and related Treasury guidance or Regulations.
	 
	 	 	 	The Election Form most recently accepted by the Committee that has become effective
shall govern the payout of the Retirement Benefit.
	 
	 	(c)	 	The lump sum payment shall be made, or installment payments shall commence, no
later than sixty (60) days after the Participant’s Benefit Distribution Date.
Remaining installments, if any, shall be paid no later than sixty (60) days after each
anniversary of the Participant’s Benefit Distribution Date.

ARTICLE 7

Termination Benefit

	7.1	 	Termination Benefit. A Participant who experiences a Termination of Employment shall
receive, as a Termination Benefit, his or her vested Account Balance, calculated as of the
close of business on or around the Participant’s Benefit Distribution Date, as determined by
the Committee in its sole discretion.

	7.2	 	Payment of Termination Benefit.

	 	(a)	 	A Participant, in connection with his or her commencement of participation in
the Plan, shall elect on an Election Form to receive the Termination Benefit in a lump
sum or pursuant to an Annual Installment Method of up to three (3) years. If a
Participant does not make any election with respect to the payment of the Termination
Benefit, then such Participant shall be deemed to have elected to receive the
Termination Benefit in a lump sum.
	 
	 	(b)	 	A Participant may change the form of payment of the Termination Benefit by
submitting an Election Form to the Committee in accordance with the following criteria:

	 	(i)	 	The election to modify the Termination Benefit shall have no
effect until at least twelve (12) months after the date on which the election is
made; and
	 
	 	(ii)	 	The first Termination Benefit payment is delayed at least five
(5) years from the Participant’s originally scheduled Benefit Distribution Date
described in Section 1.7(b) .

	 	 	 	For purposes of applying the requirements above, the right to receive the Termination
Benefit in installment payments shall be treated as the entitlement to a single
payment. The Committee shall interpret all provisions relating to changing the
Termination Benefit election under this Section 7.2 in a manner that is consistent
with Code Section 409A and related Treasury guidance or Regulations.
	 
	 	 	 	The Election Form most recently accepted by the Committee that has become effective
shall govern the payout of the Termination Benefit.

-19-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	(c)	 	Notwithstanding the foregoing, in the event a Participant’s vested Account
Balance at the time of his or her Benefit Distribution Date is less than $100,000, the
Participant’s entire vested Account Balance shall be paid to the Participant in a lump
sum.
	 
	 	(d)	 	The lump sum payment shall be made, or installment payments shall commence, no
later than sixty (60) days after the Participant’s Benefit Distribution Date.
Remaining installments, if any, shall be paid no later than sixty (60) days after each
anniversary of the Participant’s Benefit Distribution Date.

ARTICLE 8

Disability Benefit

	8.1	 	Disability Benefit. Upon a Participant’s Disability, the Participant shall receive a
Disability Benefit, which shall be equal to the Participant’s vested Account Balance,
calculated as of the close of business on or around the Participant’s Benefit Distribution
Date, as selected by the Committee in its sole discretion.

	8.2	 	Payment of Disability Benefit. The Disability Benefit shall be paid to the
Participant in a lump sum payment no later than sixty (60) days after the Participant’s
Benefit Distribution Date.

ARTICLE 9

Death Benefit

	9.1	 	Death Benefit. The Participant’s Beneficiary(ies) shall receive a Death Benefit upon
the Participant’s death which will be equal to the Participant’s vested Account Balance,
calculated as of the close of business on or around the Participant’s Benefit Distribution
Date, as selected by the Committee in its sole discretion.

	9.2	 	Payment of Death Benefit. The Death Benefit shall be paid to the Participant’s
Beneficiary(ies) in a lump sum payment no later than sixty (60) days after the Participant’s
Benefit Distribution Date.

ARTICLE 10

Beneficiary Designation

	10.1	 	Beneficiary. Each Participant shall have the right, at any time, to designate his or
her Beneficiary(ies) (both primary as well as contingent) to receive any benefits payable
under the Plan to a beneficiary upon the death of a Participant. The Beneficiary designated
under this Plan may be the same as or different from the Beneficiary designation under any
other plan of an Employer in which the Participant participates.

-20-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	10.2	 	Beneficiary Designation; Change; Spousal Consent. A Participant shall designate his
or her Beneficiary by completing and signing the Beneficiary Designation Form, and returning
it to the Committee or its designated agent. A Participant shall have the right to change a
Beneficiary by completing, signing and otherwise complying with the terms of the Beneficiary
Designation Form and the Committee’s rules and procedures, as in effect from time to time. If
the Participant names someone other than his or her spouse as a Beneficiary, the Committee
may, in its sole discretion, determine that spousal consent is required to be provided in a
form designated by the Committee, executed by such Participant’s spouse and returned to the
Committee. Upon the acceptance by the Committee of a new Beneficiary Designation Form, all
Beneficiary designations previously filed shall be canceled. The Committee shall be entitled
to rely on the last Beneficiary Designation Form filed by the Participant and accepted by the
Committee prior to his or her death.

	10.3	 	Acknowledgment. No designation or change in designation of a Beneficiary shall be
effective until received and acknowledged in writing by the Committee or its designated agent.

	10.4	 	No Beneficiary Designation. If a Participant fails to designate a Beneficiary as
provided in Sections 10.1, 10.2 and 10.3 above or, if all designated Beneficiaries predecease
the Participant or die prior to complete distribution of the Participant’s benefits, then the
Participant’s designated Beneficiary shall be deemed to be his or her surviving spouse. If
the Participant has no surviving spouse, the benefits remaining under the Plan to be paid to a
Beneficiary shall be payable to the executor or personal representative of the Participant’s
estate.

	10.5	 	Doubt as to Beneficiary. If the Committee has any doubt as to the proper Beneficiary
to receive payments pursuant to this Plan, the Committee shall have the right, exercisable in
its discretion, to cause the Participant’s Employer to withhold such payments until this
matter is resolved to the Committee’s satisfaction.

	10.6	 	Discharge of Obligations. The payment of benefits under the Plan to a Beneficiary
shall fully and completely discharge all Employers and the Committee from all further
obligations under this Plan with respect to the Participant, and that Participant’s Plan
Agreement shall terminate upon such full payment of benefits.

ARTICLE 11

Leave of Absence

	11.1	 	Paid Leave of Absence. If a Participant is authorized by the Participant’s Employer
to take a paid leave of absence from the employment of the Employer, and such leave of absence
does not constitute a separation from service, as determined by the Committee in accordance
with Code Section 409A and related Treasury guidance and Regulations, (i) the Participant
shall continue to be considered eligible for the benefits provided in Articles 4, 5, 6, 7, 8,
or 9 in accordance with the provisions of those Articles, and (ii) the Annual Deferral Amount
shall continue to be withheld during such paid leave of absence in accordance with Section
3.3.

	11.2	 	Unpaid Leave of Absence. If a Participant is authorized by the Participant’s
Employer to take an unpaid leave of absence from the employment of the Employer for any
reason, and such leave of absence does not constitute a separation from service, as determined
by the Committee in accordance with Code Section 409A and related Treasury guidance and
Regulations, such

-21-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	 	Participant shall continue to be eligible for the benefits provided in
Articles 4, 5, 6, 7, 8, or 9 in accordance with the provisions of those Articles. However, the
Participant shall be excused from fulfilling his or her Annual Deferral Amount commitment that
would otherwise have been withheld during the remainder of the Plan Year in which the unpaid
leave of absence is taken. During the unpaid leave of absence, the Participant shall not be
allowed to make any additional deferral elections. However, if the Participant returns to
employment, the Participant may elect to defer an Annual Deferral Amount for the Plan Year
following his or her return to employment and for every Plan Year thereafter while a
Participant in the Plan, provided such deferral elections are otherwise allowed and an
Election Form is delivered to and accepted by the Committee for each such election in
accordance with Section 3.3 above.
	 
	11.3	 	Leaves Resulting in Separation from Service. In the event that a Participant’s
leave of absence from his or her Employer constitutes a separation from service, as determined
by the Committee in accordance with Code Section 409A and related Treasury guidance and
Regulations, the Participant’s vested Account Balance shall be distributed to the Participant
in accordance with Article 6 or 7 of this Plan, as applicable.

ARTICLE 12

Termination of Plan, Amendment or Modification

	12.1	 	Termination of Plan. Although each Employer anticipates that it will continue the
Plan for an indefinite period of time, there is no guarantee that any Employer will continue
the Plan or will not terminate the Plan at any time in the future. Accordingly, each Employer
reserves the right to Terminate the Plan. In the event of a Termination of the Plan, the
Measurement Funds available to Participants following the Termination of the Plan shall be
comparable in number and type to those Measurement Funds available to Participants in the Plan
Year preceding the Plan Year in which the Termination of the Plan is effective. Following a
Termination of the Plan, Participant Account Balances shall
remain in the Plan until the
Participant becomes eligible for
the benefits provided in Articles
4, 5, 6, 7, 8 or 9 in accordance
with the provisions of those
Articles. The Termination of the
Plan shall not adversely affect any
Participant or Beneficiary who has
become entitled to the payment of
any benefits under the Plan as of
the date of termination.
Notwithstanding the foregoing, to
the extent permissible under Code
Section 409A and related Treasury
guidance or Regulations, during the
thirty (30) days preceding or
within twelve (12) months following
a Change in Control an Employer
shall be permitted to (i) terminate
the Plan by action of its board of
directors, and (ii) distribute the
vested Account Balances to
Participants in a lump sum no later
than twelve (12) months after the
Change in Control, provided that
all other substantially similar
arrangements sponsored by such
Employer are also terminated and
all balances in such arrangements
are distributed within twelve (12)
months of the termination of such
arrangements.

-22-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	12.2	 	Amendment.

	 	(a)	 	Any Employer may, at any time, amend or modify the Plan in whole or in part
with respect to that Employer. Notwithstanding the foregoing, (i) no amendment or
modification shall be effective to decrease the value of a Participant’s vested Account
Balance in existence at the time the amendment or modification is made, and (ii) no
amendment or modification of this Section 12.2 or Section 13.2 of the Plan shall be
effective.
	 
	 	(b)	 	Notwithstanding any provision of the Plan to the contrary, in the event that
the Company determines that any provision of the Plan may cause amounts deferred under
the Plan to become immediately taxable to any Participant under Code Section 409A, and
related Treasury guidance or Regulations, the Company may (i) adopt such amendments to
the Plan and appropriate policies and procedures, including amendments and policies
with retroactive effect, that the Company determines necessary or appropriate to
preserve the intended tax treatment of the Plan benefits provided by the Plan and/or
(ii) take such other actions as the Company determines necessary or appropriate to
comply with the requirements of Code Section 409A, and related Treasury guidance or
Regulations.

	12.3	 	Plan Agreement. Despite the provisions of Sections 12.1 and 12.2 above, if a
Participant’s Plan Agreement contains benefits or limitations that are not in this Plan
document, the Employer may only amend or terminate such provisions with the written consent of
the Participant.

	12.4	 	Effect of Payment. The full payment of the Participant’s vested Account Balance
under Articles 4, 5, 6, 7, 8, or 9 of the Plan shall completely discharge all obligations to a
Participant and his or her designated Beneficiaries under this Plan, and the Participant’s
Plan Agreement shall terminate.

ARTICLE 13

Administration

	13.1	 	Committee Duties. Except as otherwise provided in this Article 13, this Plan shall
be administered by a Committee, which shall consist of the Employee Benefits Committee of the
Company, as designated by the Compensation Committee of the
Board, or such other committee as the Board shall appoint. Members of the Committee may be
Participants under this Plan. The Committee shall also have the discretion and authority to
(i) make, amend, interpret, and enforce all appropriate rules and regulations for the
administration of this Plan, and (ii) decide or resolve any and all questions, including
benefit entitlement determinations and interpretations of this Plan, as may arise in
connection with the Plan. Any individual serving on the Committee who is a Participant
shall not vote or act on any matter relating solely to himself or herself. When making a
determination or calculation, the Committee shall be entitled to rely on information
furnished by a Participant or the Company.

-23-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	13.2	 	Administration Upon Change In Control. Within one hundred and twenty (120) days
following a Change in Control, the individuals who comprised the Committee immediately prior
to the Change in Control (whether or not such individuals are members of the Committee
following the Change in Control) may, by written consent of the majority of such individuals,
appoint an independent third party administrator (the “Administrator”) to perform any or all
of the Committee’s duties described in Section 13.1 above, including without limitation, the
power to determine any questions arising in connection with the administration or
interpretation of the Plan, and the power to make benefit entitlement determinations. Upon
and after the effective date of such appointment, (i) the Company must pay all reasonable
administrative expenses and fees of the Administrator, and (ii) the Administrator may only be
terminated with the written consent of the majority of Participants with an Account Balance in
the Plan as of the date of such proposed termination.

	13.3	 	Agents. In the administration of this Plan, the Committee or the Administrator, as
applicable, may, from time to time, employ agents and delegate to them such administrative
duties as it sees fit (including acting through a duly appointed representative) and may from
time to time consult with counsel.

	13.4	 	Binding Effect of Decisions. The decision or action of the Committee or
Administrator, as applicable, with respect to any question arising out of or in connection
with the administration, interpretation and application of the Plan and the rules and
regulations promulgated hereunder shall be final and conclusive and binding upon all persons
having any interest in the Plan.

	13.5	 	Indemnity of Committee. All Employers shall indemnify and hold harmless the members
of the Committee, any Employee to whom the duties of the Committee may be delegated, and the
Administrator against any and all claims, losses, damages, expenses or liabilities arising
from any action or failure to act with respect to this Plan, except in the case of willful
misconduct by the Committee, any of its members, any such Employee or the Administrator.

	13.6	 	Employer Information. To enable the Committee and/or Administrator to perform its
functions, the Company and each Employer shall supply full and timely information to the
Committee and/or Administrator, as the case may be, on all matters relating to the Plan, the
Trust, the Participants and their Beneficiaries, the Account Balances of the Participants, the
compensation of its Participants, the date and circumstances of the Retirement, Disability,
death or Termination of Employment of its Participants, and such other pertinent information
as the Committee or Administrator may reasonably require.

ARTICLE 14

Other Benefits and Agreements

	14.1	 	Coordination with Other Benefits. The benefits provided for a Participant and
Participant’s Beneficiary under the Plan are in addition to any other benefits available to
such Participant under any other plan or program for employees of the Participant’s Employer.
The Plan shall supplement and shall not supersede, modify or amend any other such plan or
program except as may otherwise be expressly provided.

-24-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

ARTICLE 15

Claims Procedures

	15.1	 	Presentation of Claim. Any Participant or Beneficiary of a deceased Participant
(such Participant or Beneficiary being referred to below as a “Claimant”) may deliver to the
Committee a written claim for a determination with respect to the amounts distributable to
such Claimant from the Plan. If such a claim relates to the contents of a notice received by
the Claimant, the claim must be made within sixty (60) days after such notice was received by
the Claimant. All other claims must be made within 180 days of the date on which the event
that caused the claim to arise occurred. The claim must state with particularity the
determination desired by the Claimant.

	15.2	 	Notification of Decision. The Committee shall consider a Claimant’s claim within a
reasonable time, but no later than ninety (90) days after receiving the claim. If the
Committee determines that special circumstances require an extension of time for processing
the claim, written notice of the extension shall be furnished to the Claimant prior to the
termination of the initial ninety (90) day period. In no event shall such extension exceed a
period of ninety (90) days from the end of the initial period. The extension notice shall
indicate the special circumstances requiring an extension of time and the date by which the
Committee expects to render the benefit determination. The Committee shall notify the
Claimant in writing:

	 	(a)	 	that the Claimant’s requested determination has been made, and that the claim
has been allowed in full; or
	 
	 	(b)	 	that the Committee has reached a conclusion contrary, in whole or in part, to
the Claimant’s requested determination, and such notice must set forth in a manner
calculated to be understood by the Claimant:

	 	(i)	 	the specific reason(s) for the denial of the claim, or any part
of it;
	 
	 	(ii)	 	specific reference(s) to pertinent provisions of the Plan upon
which such denial was based;
	 
	 	(iii)	 	a description of any additional material or information
necessary for the Claimant to perfect the claim, and an explanation of why such
material or information is necessary;
	 
	 	(iv)	 	an explanation of the claim review procedure set forth in Section
15.3 below; and
	 
	 	(v)	 	a statement of the Claimant’s right to bring a civil action under
ERISA Section 502(a) following an adverse benefit determination on review.

	15.3	 	Review of a Denied Claim. On or before sixty (60) days after receiving a notice from
the Committee that a claim has been denied, in whole or in part, a Claimant (or the Claimant’s
duly authorized representative) may file with the Committee a written request for a review of
the denial of the claim. The Claimant (or the Claimant’s duly authorized representative):

	 	(a)	 	may, upon request and free of charge, have reasonable access to, and copies of,
all documents, records and other information relevant (as defined in applicable ERISA
regulations) to the claim for benefits;
	 
	 	(b)	 	may submit written comments or other documents; and/or

-25-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	 	(c)	 	may request a hearing, which the Committee, in its sole discretion, may grant.

	15.4	 	Decision on Review. The Committee shall render its decision on review promptly, and
no later than sixty (60) days after the Committee receives the Claimant’s written request for
a review of the denial of the claim. If the Committee determines that special circumstances
require an extension of time for processing the claim, written notice of the extension shall
be furnished to the Claimant prior to the termination of the initial sixty (60) day period.
In no event shall such extension exceed a period of sixty (60) days from the end of the
initial period. The extension notice shall indicate the special circumstances requiring an
extension of time and the date by which the Committee expects to render the benefit
determination. In rendering its decision, the Committee shall take into account all comments,
documents, records and other information submitted by the Claimant relating to the claim,
without regard to whether such information was submitted or considered in the initial benefit
determination. The decision must be written in a manner calculated to be understood by the
Claimant, and it must contain:

	 	(a)	 	specific reasons for the decision;
	 
	 	(b)	 	specific reference(s) to the pertinent Plan provisions upon which the decision
was based;
	 
	 	(c)	 	a statement that the Claimant is entitled to receive, upon request and free of
charge, reasonable access to and copies of, all documents, records and other
information relevant (as defined in applicable ERISA regulations) to the Claimant’s
claim for benefits; and
	 
	 	(d)	 	a statement of the Claimant’s right to bring a civil action under ERISA Section
502(a).

	15.5	 	Legal Action. A Claimant’s compliance with the foregoing provisions of this Article
15 is a mandatory prerequisite to a Claimant’s right to commence any legal action with respect
to any claim for benefits under this Plan. 

ARTICLE 16

Trust

	16.1	 	Establishment of the Trust. In order to provide assets from which to fulfill its
obligations to the Participants and their beneficiaries under the Plan, the Company may
establish a trust by a trust agreement with a third party, the trustee, to
which each Employer may, in its discretion, contribute cash or other property, including
securities issued by the Company, to provide for the benefit payments under the Plan, (the
“Trust”).

	16.2	 	Interrelationship of the Plan and the Trust. The provisions of the Plan and the Plan
Agreement shall govern the rights of a Participant to receive distributions pursuant to the
Plan. The provisions of the Trust shall govern the rights of the Employers, Participants and
the creditors of the Employers to the assets transferred to the Trust. Each Employer shall at
all times remain liable to carry out its obligations under the Plan.

	16.3	 	Distributions From the Trust. Each Employer’s obligations under the Plan may be
satisfied with Trust assets distributed pursuant to the terms of the Trust, and any such
distribution shall reduce the Employer’s obligations under this Plan.

-26-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

ARTICLE 17

Miscellaneous

	17.1	 	Status of Plan. The Plan is intended to be a plan that is not qualified within the
meaning of Code Section 401(a) and that “is unfunded and is maintained by an employer
primarily for the purpose of providing deferred compensation for a select group of management
or highly compensated employees” within the meaning of ERISA Sections 201(2), 301(a)(3) and
401(a)(1). The Plan shall be administered and interpreted (i) in a manner consistent with
that intent, and (ii) in accordance with Code Section 409A and related Treasury guidance and
Regulations.

	17.2	 	Unsecured General Creditor. Participants and their Beneficiaries, heirs, successors
and assigns shall have no legal or equitable rights, interests or claims in any property or
assets of an Employer. For purposes of the payment of benefits under this Plan, any and all
of an Employer’s assets shall be, and remain, the general, unpledged unrestricted assets of
the Employer. An Employer’s obligation under the Plan shall be merely that of an unfunded and
unsecured promise to pay money in the future.

	17.3	 	Employer’s Liability. An Employer’s liability for the payment of benefits shall be
defined only by the Plan and the Plan Agreement, as entered into between the Employer and a
Participant. An Employer shall have no obligation to a Participant under the Plan except as
expressly provided in the Plan and his or her Plan Agreement.

	17.4	 	Nonassignability. Neither a Participant nor any other person shall have any right to
commute, sell, assign, transfer, pledge, anticipate, mortgage or otherwise encumber, transfer,
hypothecate, alienate or convey in advance of actual receipt, the amounts, if any, payable
hereunder, or any part thereof, which are, and all rights to which are expressly declared to
be, unassignable and non-transferable. No part of the amounts payable shall, prior to actual
payment, be subject to seizure, attachment, garnishment or sequestration for the payment of
any debts, judgments, alimony or separate maintenance owed by a Participant or any other
person, be transferable by operation of law in the event of a Participant’s or any other
person’s bankruptcy or insolvency or be transferable to a spouse as a result of a property
settlement or otherwise.

	17.5	 	Not a Contract of Employment. The terms and conditions of this Plan shall not be
deemed to constitute a contract of employment between any Employer and the Participant. Such
employment is hereby acknowledged to be an “at will” employment relationship that can be
terminated at any time for any reason, or no reason, with or without cause, and with or
without notice, unless expressly provided in a written employment agreement. Nothing in this
Plan shall be deemed to give a Participant the right to be retained in the service of any
Employer, either as an Employee or a Director, or to interfere with the right of any Employer
to discipline or discharge the Participant at any time.

	17.6	 	Furnishing Information. A Participant or his or her Beneficiary will cooperate with
the Committee by furnishing any and all information requested by the Committee and take such
other actions as may be requested in order to facilitate the administration of the Plan and
the payments of benefits hereunder, including but not limited to taking such physical
examinations as the Committee may deem necessary.

-27-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	17.7	 	Terms. Whenever any words are used herein in the masculine, they shall be construed
as though they were in the feminine in all cases where they would so apply; and whenever any
words are used herein in the singular or in the plural, they shall be construed as though they
were used in the plural or the singular, as the case may be, in all cases where they would so
apply.

	17.8	 	Captions. The captions of the articles, sections and paragraphs of this Plan are for
convenience only and shall not control or affect the meaning or construction of any of its
provisions.

	17.9	 	Governing Law. Subject to ERISA, the provisions of this Plan shall be construed and
interpreted according to the internal laws of the State of Florida without regard to its
conflicts of laws principles.

	17.10	 	Notice. Any notice or filing required or permitted to be given to the Committee
under this Plan shall be sufficient if in writing and hand-delivered, or sent by registered or
certified mail, to the address below:

	 	 	 	 	 
	 

	 	Noven Pharmaceuticals, Inc.	 	 
	 

	 	 	 	 
	 

	 	Attn: Vice President, Human Resources
 

	 	 
	 

	 	11960 SW 144th Street	 	 
	 

	 	 	 	 
	 

	 	Miami, Florida 33186	 	 
	 

	 	 	 	 

	 	 	Such notice shall be deemed given as of the date of delivery or, if delivery is made by
mail, as of the date shown on the postmark on the receipt for registration or certification.
	 
	 	 	Any notice or filing required or permitted to be given to a Participant under this Plan
shall be sufficient if in writing and hand-delivered, or sent by mail, to the last known
address of the Participant.
	 
	17.11	 	Successors. The provisions of this Plan shall bind and inure to the benefit of the
Participant’s Employer and its successors and assigns and the Participant and the
Participant’s designated Beneficiaries.
	 
	17.12	 	Spouse’s Interest. The interest in the benefits hereunder of a spouse of a
Participant who has predeceased the Participant shall automatically pass to the Participant
and shall not be transferable by such spouse in any manner, including but not limited to such
spouse’s will, nor shall such interest pass under the laws of intestate succession.
	 
	17.13	 	Validity. In case any provision of this Plan shall be illegal or invalid for any
reason, said illegality or invalidity shall not affect the remaining parts hereof, but this
Plan shall be construed and enforced as if such illegal or invalid provision had never been
inserted herein.
	 
	17.14	 	Incompetent. If the Committee determines in its discretion that a benefit under
this Plan is to be paid to a minor, a person declared incompetent or to a person incapable of
handling the disposition of that person’s property, the Committee may direct payment of such
benefit to the guardian, legal representative or person having the care and custody of such
minor, incompetent or incapable person. The Committee may require proof of minority,
incompetence, incapacity or guardianship, as it may deem appropriate prior to distribution of
the benefit. Any payment of a benefit shall be a payment for the account of the Participant
and the Participant’s Beneficiary, as the case may be, and shall be a complete discharge of
any liability under the Plan for such payment amount.

-28-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

	17.15	 	Court Order. The Committee is authorized to comply with any court order in any
action in which the Plan or the Committee has been named as a party, including any action
involving a determination of the rights or interests in a Participant’s benefits under the
Plan. Notwithstanding the foregoing, the Committee shall interpret this provision in a manner
that is consistent with Code Section 409A and other applicable tax law. In addition, if
necessary to comply with a qualified domestic relations order, as defined in Code Section
414(p)(1)(B), pursuant to which a court has determined that a spouse or former spouse of a
Participant has an interest in the Participant’s benefits under the Plan, the Committee, in
its sole discretion, shall have the right to immediately distribute the spouse’s or former
spouse’s interest in the Participant’s benefits under the Plan to such spouse or former
spouse.

	17.16	 	Distribution in the Event of Income Inclusion Under 409A. If any portion of a
Participant’s Account Balance under this Plan is required to be included in income by the
Participant prior to receipt due to a failure of this Plan to meet the requirements of Code
Section 409A and related Treasury guidance or Regulations, the Participant may petition the
Committee or Administrator, as applicable, for a distribution of that portion of his or her
Account Balance that is required to be included in his or her income. Upon the grant of such
a petition, which grant shall not be unreasonably withheld, the Participant’s Employer shall
distribute to the Participant an amount equal to the portion of his or her Account Balance
required to be included in income as a result of the failure of the Plan to meet the
requirements of Code Section 409A and related Treasury guidance or Regulations, which amount
shall not exceed the Participant’s unpaid vested Account Balance under the Plan. If the
petition is granted, such distribution shall be made within ninety
(90) days of the date when the Participant’s petition is granted. Such a distribution shall
affect and reduce the Participant’s benefits to be paid under this Plan.

	17.17	 	Deduction Limitation on Benefit Payments. If an Employer reasonably anticipates
that the Employer’s deduction with respect to any distribution from this Plan would be limited
or eliminated by application of Code Section 162(m), then to the extent deemed necessary by
the Employer to ensure that the entire amount of any distribution from this Plan is
deductible, the Employer may delay payment of any amount that would otherwise be distributed
from this Plan. Any amounts for which distribution is delayed pursuant to this Section shall
continue to be credited/debited with additional amounts in accordance with Section 3.10 above.
The delayed amounts (and any amounts credited thereon) shall be distributed to the
Participant (or his or her Beneficiary in the event of the Participant’s death) at the
earliest date the Employer reasonably anticipates that the deduction of the payment of the
amount will not be limited or eliminated by application of Code Section 162(m).

	17.18	 	Insurance. The Employers, on their own behalf or on behalf of the trustee of the
Trust, and, in their sole discretion, may apply for and procure insurance on the life of the
Participant, in such amounts and in such forms as the Trust may choose. The Employers or the
trustee of the Trust, as the case may be, shall be the sole owner and beneficiary of any such
insurance. The Participant shall have no interest whatsoever in any such policy or policies,
and at the request of the Employers shall submit to medical examinations and supply such
information and execute such documents as may be required by the insurance company or
companies to whom the Employers have applied for insurance.

-29-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

IN WITNESS WHEREOF, the Company has amended and restated this Plan document as of September
15, 2006.

	 	 	 
	 

	 	“Company”
	 

	 	Noven Pharmaceuticals, Inc.,
	 

	 	a Delaware corporation
	 
	 	 
	 

	 	By: /s/ Robert C. Strauss
	 

	 	 
	 

	 	Title: President, CEO & Chairman of the Board

-30-

 

Noven Pharmaceuticals, Inc.

Nonqualified Deferred Compensation Plan

Master Plan Document

APPENDIX A

LIMITED TRANSITION RELIEF MADE AVAILABLE IN ACCORDANCE WITH CODE SECTION 409A AND RELATED

TREASURY GUIDANCE AND REGULATIONS

Unless otherwise provided below, the capitalized terms below shall have the same meaning as
provided in the Plan.

	 	1.	 	Opportunity to Make New Distribution Elections. Notwithstanding the required
deadline for the submission of an initial distribution election described in Articles 4, 5,
6 and 7, the Committee may, as permitted by Code Section 409A and related Treasury guidance
or Regulations, provide a limited period in which Participants may make new distribution
elections by submitting an Election Form on or before the deadline established by the
Committee, which in no event shall be later than December 31, 2006. Any distribution
election made in accordance with the requirements established by the Committee, pursuant to
this section, shall not be treated as a change in the form or timing of a Participant’s
benefit payment for purposes Code Section 409A or the Plan.
	 
	 	 	 	The Committee shall interpret all provisions relating to an election submitted in accordance
with this section in a manner that is consistent with Code Section 409A and related Treasury
guidance or Regulations. If any distribution election submitted in accordance with this
section either (i) relates to payments that a Participant would otherwise receive in 2006,
or (ii) would cause payments to be made in 2006, such election shall not be effective.

-31-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]